

{"id":38130,"date":"2024-07-09T05:10:18","date_gmt":"2024-07-09T05:10:18","guid":{"rendered":"https:\/\/zydq.1006ss.com\/?p=38130"},"modified":"2024-07-09T05:10:18","modified_gmt":"2024-07-09T05:10:18","slug":"%e3%80%90%e7%bb%bc%e8%bf%b0%e3%80%91%e8%a1%80%e6%b6%b2%e9%80%8f%e6%9e%90%e6%82%a3%e8%80%85%e7%98%99%e7%97%92%e7%97%87%e7%9a%84%e5%8f%91%e7%97%85%e6%9c%ba%e5%88%b6%e5%8f%8a%e8%8d%af%e7%89%a9%e6%b2%bb","status":"publish","type":"post","link":"http:\/\/zydq.1006ss.com\/?p=38130","title":{"rendered":"\u3010\u7efc\u8ff0\u3011\u8840\u6db2\u900f\u6790\u60a3\u8005\u7619\u75d2\u75c7\u7684\u53d1\u75c5\u673a\u5236\u53ca\u836f\u7269\u6cbb\u7597\u8fdb\u5c55"},"content":{"rendered":"<p>\u6c64\u6653\u9759&nbsp;&nbsp;\u6885\u957f\u6797<\/p>\n<p>\uff08\u6d77\u519b\u519b\u533b\u5927\u5b66\u7b2c\u4e8c\u9644\u5c5e\u533b\u9662\u80be\u810f\u75c5\u79d1\uff0c\u4e0a\u6d77 200003\uff09<\/p>\n<p>\u901a\u4fe1\u4f5c\u8005\uff1a\u6885\u957f\u6797\uff0cEmail\uff1achlmei1954@126.com<\/p>\n<p>DOI\uff1a10.3760\/cma.j.cn441217-20230413-00420<\/p>\n<p>\u6458 \u8981&nbsp;\u6162\u6027\u80be\u810f\u75c5\u76f8\u5173\u6027\u7619\u75d2\u75c7\uff08chronic kidney disease-associated pruritus\uff0cCKD-aP\uff09\u662f\u8840\u6db2\u900f\u6790\u60a3\u8005\u5e38\u89c1\u4e14\u96be\u4ee5\u5fcd\u53d7\u7684\u5e76\u53d1\u75c7\uff0c\u4e0d\u4ec5\u4e25\u91cd\u5f71\u54cd\u5176\u751f\u6d3b\u8d28\u91cf\u548c\u8eab\u5fc3\u5065\u5eb7\uff0c\u800c\u4e14\u589e\u52a0\u5176\u8fdc\u671f\u6b7b\u4ea1\u98ce\u9669\u3002CKD-aP\u7684\u53d1\u75c5\u673a\u5236\u4ecd\u4e0d\u660e\u786e\uff0c\u514d\u75ab\u708e\u75c7\u5931\u8c03\u3001\u5185\u6e90\u6027\u963f\u7247\u7c7b\u7cfb\u7edf\u5931\u8861\u3001\u4ee3\u8c22\u4ea7\u7269\u5f02\u5e38\u84c4\u79ef\u3001\u76ae\u80a4\u5e72\u71e5\u75c7\u3001\u7ec4\u80fa\u6c34\u5e73\u5f02\u5e38\u3001\u7532\u72b6\u65c1\u817a\u529f\u80fd\u4ea2\u8fdb\u7b49\u56e0\u7d20\u90fd\u88ab\u8bc1\u5b9e\u4e0e\u5176\u76f8\u5173\u3002CKD-aP\u76ee\u524d\u7f3a\u4e4f\u6ee1\u610f\u3001\u7279\u6548\u7684\u6cbb\u7597\u7b56\u7565\uff0c\u4e3b\u8981\u5305\u62ec\u836f\u7269\u6cbb\u7597\u3001\u975e\u836f\u7269\u6cbb\u7597\u548c\u900f\u6790\u65b9\u5f0f\u8c03\u6574\u3002\u8be5\u6587\u4e3b\u8981\u5c31CKD-aP\u7684\u53d1\u75c5\u673a\u5236\u53ca\u836f\u7269\u6cbb\u7597\u8fdb\u5c55\u4f5c\u4e00\u7efc\u8ff0\u3002\u5173\u952e\u8bcd&nbsp;\u80be\u900f\u6790\uff1b\u7619\u75d2\u75c7\uff1b\u836f\u7269\u7597\u6cd5\uff1b\u53d1\u75c5\u673a\u5236\u6162\u6027\u80be\u810f\u75c5\uff08chronic kidney disease\uff0cCKD\uff09\u662f\u5371\u5bb3\u4eba\u7c7b\u5065\u5eb7\u7684\u91cd\u8981\u516c\u5171\u536b\u751f\u95ee\u9898\uff0c\u5176\u4e2d\u90e8\u5206\u75c5\u4f8b\u8fdb\u5c55\u81f3\u7ec8\u672b\u671f\u80be\u75c5\uff08end-stage kidney disease\uff0cESKD\uff09\u3002\u8840\u6db2\u900f\u6790\uff08hemodialysis\uff0cHD\uff09\u662f\u6cbb\u7597ESKD\u7684\u4e3b\u8981\u65b9\u6cd5\u4e4b\u4e00\u3002HD\u60a3\u8005\u53ef\u51fa\u73b0\u5404\u79cd\u5e76\u53d1\u75c7\uff0c\u7619\u75d2\u75c7\u662f\u5176\u5e38\u89c1\u5e76\u53d1\u75c7\u4e4b\u4e00\uff0c\u65e2\u5f80\u88ab\u79f0\u4e3a\u5c3f\u6bd2\u75c7\u6027\u76ae\u80a4\u7619\u75d2\u75c7\uff08uremic pruritus\uff0cUP\uff09\u3002\u7531\u4e8e\u5c3f\u6bd2\u75c7\u4e25\u91cd\u7a0b\u5ea6\u4e0e\u7619\u75d2\u75c7\u4e25\u91cd\u7a0b\u5ea6\u5b58\u5728\u4e0d\u4e00\u81f4\u6027\uff0c\u73b0\u591a\u4f7f\u7528CKD\u76f8\u5173\u7619\u75d2\u75c7\uff08CKD-associated pruritus\uff0cCKD-aP\uff09\u7684\u6982\u5ff5<sup>\uff3b1\uff3d<\/sup>\u3002CKD-aP\u662f\u6307\u7ee7\u53d1\u4e8e\u80be\u810f\u75c5\u7684\u7619\u75d2\u75c7\uff0c\u4e3b\u8981\u8868\u73b0\u4e3a\u5c40\u90e8\u6216\u5168\u8eab\u76ae\u80a4\u4e0d\u540c\u7a0b\u5ea6\u7684\u7619\u75d2\uff0c\u4f34\u6216\u4e0d\u4f34\u6709\u76ae\u75b9\uff0c\u5448\u53d1\u4f5c\u6027\uff0c\u591c\u95f4\u8f83\u767d\u5929\u52a0\u91cd\uff0c\u53d1\u4f5c\u6301\u7eed\u65f6\u95f4\u4e0d\u7b49<sup>\uff3b1\uff3d<\/sup>\u3002\u7619\u75d2\u75c7\u53ef\u5f71\u54cdCKD\u60a3\u8005\u7684\u7761\u7720\u3001\u60c5\u7eea\u72b6\u6001\u3001\u793e\u4ea4\u529f\u80fd\uff0c\u5e76\u53ef\u5bfc\u81f4\u6291\u90c1\u751a\u81f3\u81ea\u6740\u503e\u5411\u4ee5\u53ca\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u53d1\u751f\uff0c\u4e25\u91cd\u964d\u4f4e\u5176\u751f\u6d3b\u8d28\u91cf\uff0c\u5e76\u4e14CKD-aP\u4e5f\u662fHD\u60a3\u8005\u75c5\u6b7b\u7387\u7684\u72ec\u7acb\u9884\u6d4b\u56e0\u7d20<sup>\uff3b2\uff3d<\/sup>\u3002CKD-aP\u7684\u53d1\u75c5\u673a\u5236\u76ee\u524d\u5c1a\u4e0d\u660e\u786e\uff0c\u4e14\u4e34\u5e8a\u5b9e\u8df5\u4e2d\u6cbb\u7597\u6548\u679c\u6709\u9650\uff0c\u7ed9ESKD\u60a3\u8005\u548c\u533b\u62a4\u4eba\u5458\u90fd\u9020\u6210\u4e86\u8f83\u5927\u56f0\u6270\u3002\u672c\u6587\u805a\u7126HD\u60a3\u8005\u7619\u75d2\u75c7\uff0c\u7ed3\u5408\u56fd\u5185\u5916\u7814\u7a76\uff0c\u7efc\u5408\u9610\u8ff0CKD-aP\u7684\u53d1\u75c5\u673a\u5236\u53ca\u836f\u7269\u6cbb\u7597\u7684\u8fdb\u5c55\u3002<\/p>\n<h2>\u4e00\u3001&nbsp;\u6d41\u884c\u75c5\u5b66<\/h2>\n<p>\u5728\u5168\u7403\u8303\u56f4\u5185\uff0cCKD-aP\u5728ESKD\u60a3\u8005\u4e2d\u5747\u6709\u8f83\u9ad8\u7a0b\u5ea6\u7684\u6d41\u884c\uff0c\u4f46\u73b0\u6709\u62a5\u9053\u663e\u793a\uff0c\u5728\u4e0d\u540c\u56fd\u5bb6\u751a\u81f3\u540c\u4e00\u56fd\u5bb6\u4e0d\u540c\u7814\u7a76\u4e2d\u5fc3\u6240\u62a5\u9053\u7684\u53d1\u75c5\u7387\u5b58\u5728\u8f83\u5927\u5dee\u5f02\u3002\u603b\u4f53\u6765\u8bf4\uff0cCKD-aP\u5728ESKD\u60a3\u8005\u4e2d\u53d1\u75c5\u7387\u4e3a20%\uff5e90%\u4e0d\u7b49<sup>\uff3b3\uff3d<\/sup>\u3002\u4e00\u9879\u5305\u62ec\u7f8e\u56fd\u3001\u65e5\u672c\u7b4912\u4e2a\u56fd\u5bb6\u7684\u5927\u578b\u7814\u7a76\u5bf9\u900f\u6790\u9884\u540e\u4e0e\u5b9e\u8df5\u6a21\u5f0f\uff08Dialysis Outcomes and Practice Patterns Study\uff0cDOPPS\uff09\u8fdb\u884c\u4e86\u5206\u6790\uff0c\u7ed3\u679c\u663e\u793a\uff0cDOPPS 1\uff5e5\u671f\u4e2d\uff0c\u4e2d\u5ea6\u81f3\u6781\u91cd\u5ea6\u7619\u75d2\u75c7\u60a3\u75c5\u7387\u5206\u522b\u4e3a46%\u300142%\u300142%\u300140%\u548c37%<sup>\uff3b4\uff3d<\/sup>\u3002\u6211\u56fd\u4e00\u9879\u835f\u8403\u5206\u6790\u7814\u7a76\u663e\u793a\uff0c\u6210\u5e74\u900f\u6790\u60a3\u8005CKD-aP\u7684\u60a3\u75c5\u7387\u4e3a18%\uff5e98%\uff0cCKD-aP\u5e73\u5747\u60a3\u75c5\u7387\u8fbe55%\uff0895%&nbsp;CI&nbsp;49%\uff5e61%\uff09<sup>\uff3b5\uff3d<\/sup>\u3002\u6700\u65b0DOPPS\u8c03\u67e5\u7ed3\u679c\u663e\u793a\uff0c\u5728\u6211\u56fd\u63a5\u53d7\u8c03\u67e5\u76841 239\u4f8bHD\u60a3\u8005\u4e2d\uff0c82%\u60a3\u8005\u5b58\u5728\u4e0d\u540c\u7a0b\u5ea6\u7684\u7619\u75d2\u75c7\uff0c\u5176\u4e2d\u4e2d\u7b49\u7a0b\u5ea6\u4ee5\u4e0a\u7619\u75d2\u75c7\u60a3\u8005\u6bd4\u4f8b\u9ad8\u8fbe39%\uff0c\u800c\u4e25\u91cd\u6216\u6781\u91cd\u5ea6\u7619\u75d2\u75c7\u60a3\u8005\u8fbe\u523019%<sup>\uff3b6\uff3d<\/sup>\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u8bb8\u591aCKD\u60a3\u8005\u5bf9\u7619\u75d2\u75c7\u7684\u91cd\u89c6\u7a0b\u5ea6\u4e0d\u591f\u6216\u533b\u7597\u673a\u6784\u5bf9\u7619\u75d2\u75c7\u7684\u8bca\u65ad\u5b58\u5728\u4e00\u5b9a\u7a0b\u5ea6\u7684\u4f4e\u4f30\uff0c\u8fd9\u53ef\u80fd\u5bfc\u81f4\u90e8\u5206\u75c5\u4f8b\u62a5\u544a\u7f3a\u5931<sup>\uff3b4\uff3d<\/sup>\u3002<\/p>\n<h2>\u4e8c\u3001&nbsp;\u53d1\u75c5\u673a\u5236<\/h2>\n<p>CKD-aP\u7684\u75c5\u7406\u751f\u7406\u673a\u5236\u590d\u6742\uff0c\u88ab\u8ba4\u4e3a\u7531\u591a\u79cd\u673a\u5236\u76f8\u4e92\u4f5c\u7528\u6240\u4ecb\u5bfc\uff0c\u4f46\u5177\u4f53\u53d1\u75c5\u673a\u5236\u5c1a\u672a\u5b8c\u5168\u9610\u660e\uff0c\u6f5c\u5728\u7684\u53d1\u75c5\u673a\u5236\u5305\u62ec\u514d\u75ab\u708e\u75c7\u5931\u8c03\u3001\u5185\u6e90\u6027\u963f\u7247\u7c7b\u7cfb\u7edf\u5931\u8861\u3001\u4ee3\u8c22\u7269\u5f02\u5e38\u84c4\u79ef\u548c\u76ae\u80a4\u5e72\u71e5\u75c7\u7b49\u3002<\/p>\n<h3>\uff08\u4e00\uff09&nbsp;\u514d\u75ab\u708e\u75c7\u5931\u8c03<\/h3>\n<p>CKD\u53ef\u5f15\u53d1\u5168\u8eab\u5fae\u708e\u75c7\u72b6\u6001\uff0cHD\u60a3\u8005\u663e\u793a\u51fa\u7684\u514d\u75ab\u7ec6\u80de\u6d78\u6da6\u5f02\u5e38\u6216\u514d\u75ab\u708e\u6027\u56e0\u5b50\u8868\u8fbe\u4e0a\u8c03\u5747\u63d0\u793a\u7619\u75d2\u75c7\u7684\u53d1\u75c5\u4e0e\u8bf8\u591a\u514d\u75ab\u708e\u75c7\u5931\u8c03\u5bc6\u5207\u76f8\u5173\u3002\u6709\u7814\u7a76\u663e\u793a\uff0c\u4e00\u7cfb\u5217\u8c03\u8282\u514d\u75ab\u6216\u708e\u75c7\u7684\u56e0\u7d20\u5982\u767d\u7ec6\u80de\u5347\u9ad8\u3001\u4f4e\u86cb\u767d\u8840\u75c7\u3001\u9ad8\u94c1\u86cb\u767d\u8840\u75c7\u4e0e\u4e2d\u91cd\u5ea6\u7619\u75d2\u75c7\u6709\u5173<sup>\uff3b7\uff3d<\/sup>\u3002\u6b64\u5916\uff0c1\u578b\u8f85\u52a9\u6027T\u7ec6\u80de\u3001C\u53cd\u5e94\u86cb\u767d\u3001\u767d\u7ec6\u80de\u4ecb\u7d20\uff08interleukin\uff0cIL\uff09-6\u3001IL-2\u7b49\u708e\u75c7\u6807\u5fd7\u7269\u5728\u7619\u75d2\u75c7HD\u60a3\u8005\u4e2d\u663e\u8457\u5347\u9ad8<sup>\uff3b8-9\uff3d<\/sup>\u3002\u8fd1\u5e74\u6765\u53d1\u73b0\u4e00\u7cfb\u5217\u7ec6\u80de\u56e0\u5b50\u53c2\u4e0e\u7619\u75d2\u75c7\u7684\u53d1\u75c5\u673a\u5236\uff0c\u5305\u62ecIL-2\u3001IL-4\u3001IL-13\u548cIL-31<sup>\uff3b10\uff3d<\/sup>\u3002IL-31\u662f\u6700\u65e9\u53d1\u73b0\u7684\u4e0e\u7619\u75d2\u75c7\u76f8\u5173\u7684\u7ec6\u80de\u56e0\u5b50\uff0c\u7531\u5305\u62ecCD4<sup> &nbsp;<\/sup>T\u6dcb\u5df4\u7ec6\u80de\u3001\u80a5\u5927\u7ec6\u80de\u7b49\u5728\u5185\u7684\u591a\u79cd\u7ec6\u80de\u5206\u6ccc\uff0c\u4e0e\u611f\u89c9\u795e\u7ecf\u5143\u4e0a\u7684IL-31\u53d7\u4f53\u7ed3\u5408\uff0c\u6fc0\u6d3b\u8fa3\u6912\u7d20\u53d7\u4f531\u548c\u77ac\u65f6\u53d7\u4f53\u7535\u4f4dA1\u79bb\u5b50\u901a\u9053\uff0c\u4ece\u800c\u5f15\u53d1\u7619\u75d2\u75c7\u3002IL-31\u53d7\u4f53\u5728\u611f\u89c9\u795e\u7ecf\u5143\u4e0a\u7684\u8868\u8fbe\u548c\u5206\u5e03\u8868\u660e\u5176\u662f\u4ecb\u5bfc\u7619\u75d2\u75c7\u4ea7\u751f\u6700\u76f4\u63a5\u7684\u7ec6\u80de\u56e0\u5b50\u3002IL-31\u8fd8\u53ef\u4fc3\u8fdbIL-31\u53d7\u4f53\u611f\u89c9\u795e\u7ecf\u7ea4\u7ef4\u7684\u4f38\u957f\u548c\u5206\u652f\uff0c\u5bfc\u81f4\u7619\u75d2\u75c7\u52a0\u91cd\u3002IL-31\u6ce8\u5c04\u5230\u5c0f\u9f20\u76ae\u80a4\u540e\u76f4\u63a5\u5f15\u8d77\u7619\u75d2\u75c7\uff0c\u963b\u65ad\u9488\u5bf9IL-31\u6216\u5176\u53d7\u4f53\u7684\u6297\u4f53\u53ef\u8fc5\u901f\u7f13\u89e3\u7619\u75d2\u75c7\u3002\u4e0eIL-31\u7c7b\u4f3c\uff0cIL-13\u53ef\u76f4\u63a5\u6fc0\u6d3b\u795e\u7ecf\u5143\u5f15\u8d77\u7619\u75d2\u75c7\uff0c\u800cIL-4\u901a\u8fc7\u611f\u89c9\u795e\u7ecf\u5143\u589e\u52a0\u5bf9\u5176\u4ed6\u7619\u75d2\u75c7\u4ecb\u8d28\u7684\u53cd\u5e94\u6027\u3002<\/p>\n<h3>\uff08\u4e8c\uff09&nbsp;\u5185\u6e90\u6027\u963f\u7247\u7c7b\u7cfb\u7edf\u5931\u8861<\/h3>\n<p>\u963f\u7247\u7c7b\u7cfb\u7edf\u4e3b\u8981\u75313\u4e2a\u540c\u6e90\u7684G\u86cb\u767d\u8026\u8054\u53d7\u4f53\u7ec4\u6210\uff0c\u5373\u03bc-\u963f\u7247\u53d7\u4f53\uff08\u03bc-opioid receptors\uff0cMOR\uff09\u3001\u03b4-\u963f\u7247\u53d7\u4f53\uff08\u03b4- opioid receptors\uff0cDOR\uff09\u548c\u03ba-\u963f\u7247\u53d7\u4f53\uff08\u03ba-opioid receptors\uff0cKOR\uff09\u3002\u963f\u7247\u7c7b\u5316\u5408\u7269\u901a\u8fc7\u8c03\u63a7\u810a\u9ad3\u80cc\u89d2\u7a81\u89e6\u540e\u7ec6\u80de\u819c\u4e0aMOR\u548cKOR\u7684\u76f8\u4e92\u4f5c\u7528\u6765\u4ecb\u5bfc\u7619\u75d2\u75c7\u7684\u53d1\u751f\uff0cDOR\u5bf9\u7619\u75d2\u75c7\u65e0\u8c03\u8282\u4f5c\u7528\uff0cMOR\u8fc7\u5ea6\u6fc0\u6d3b\u548cKOR\u6d3b\u6027\u6291\u5236\u5747\u53ef\u5bfc\u81f4\u7619\u75d2\u75c7\u53d1\u751f<sup>\uff3b11\uff3d<\/sup>\u3002CKD\u60a3\u8005\u76ae\u80a4\u7ec6\u80de\u548c\u514d\u75ab\u7ec6\u80de\u7684MOR\u5f02\u5e38\u6fc0\u6d3b\u3001KOR\u6c34\u5e73\u4e0b\u964d\u5747\u53ef\u5bfc\u81f4\u7619\u75d2\u75c7<sup>\uff3b12\uff3d<\/sup>\u3002\u5185\u6e90\u6027\u963f\u7247\u7c7b\u7cfb\u7edf\u5931\u8861\u673a\u5236\u662f\u8fd1\u5e74\u6765\u4f7f\u7528MOR\u62ee\u6297\u5242\u6216KOR\u6fc0\u52a8\u5242\u6cbb\u7597CKD-aP\u7684\u91cd\u8981\u7406\u8bba\u57fa\u7840\uff0c\u591a\u9879\u7814\u7a76\u8868\u660eMOR\u62ee\u6297\u5242\u6216KOR\u6fc0\u52a8\u5242\u5747\u53ef\u4e0d\u540c\u7a0b\u5ea6\u5730\u7f13\u89e3HD\u60a3\u8005\u7684\u7619\u75d2\u75c7<sup>\uff3b13\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u4e09\uff09&nbsp;\u4ee3\u8c22\u4ea7\u7269\u5f02\u5e38\u84c4\u79ef<\/h3>\n<p>HD\u60a3\u8005\u5e38\u56e0\u80be\u8870\u7aed\u3001\u900f\u6790\u4e0d\u5145\u5206\u6216\u5176\u4ed6\u539f\u56e0\u5b58\u5728\u6bd2\u6027\u4ee3\u8c22\u4ea7\u7269\u5f02\u5e38\u79ef\u7d2f\uff0c\u8fdb\u800c\u8bf1\u53d1\u76ae\u80a4\u7619\u75d2\u75c7\uff0c\u5982\u9ad8\u8840\u78f7\u4e0e\u9499\u7ed3\u5408\u5f62\u6210\u78f7\u9178\u9499\u6c89\u79ef\u4e8e\u76ae\u80a4\u6216\u5176\u4ed6\u7ec4\u7ec7\u4e2d\uff0c\u6c89\u79ef\u7269\u8fdb\u4e00\u6b65\u523a\u6fc0\u5c40\u90e8\u795e\u7ecf\u7ea4\u7ef4\u8bf1\u53d1\u7619\u75d2\u75c7<sup>\uff3b14\uff3d<\/sup>\u3002Hsu\u7b49<sup>\uff3b15\uff3d<\/sup>\u53d1\u73b0\u8840\u6e05\u94dd\u9ad8\u7684HD\u60a3\u8005\u7619\u75d2\u75c7\u53d1\u75c5\u7387\u589e\u52a0\uff0c\u8868\u660e\u8840\u6e05\u94dd\u4e5f\u662f\u7619\u75d2\u75c7\u53d1\u75c5\u7684\u5f71\u54cd\u56e0\u7d20\u3002\u7814\u7a76\u8fd8\u53d1\u73b0\u9178\u6027\u7269\u8d28\u84c4\u79ef\u4e5f\u4e0e\u7619\u75d2\u75c7\u76f8\u5173<sup>\uff3b16\uff3d<\/sup>\u3002\u591a\u9879\u7814\u7a76\u663e\u793aESKD\u60a3\u8005\u80be\u79fb\u690d\u540e\uff0c\u76ae\u80a4\u95ee\u9898\u548c\u7619\u75d2\u75c7\u53d1\u751f\u7387\u964d\u4f4e\uff0c\u8fdb\u4e00\u6b65\u63d0\u793a\u5c3f\u6bd2\u75c7\u6bd2\u7d20\u4e0e\u7619\u75d2\u75c7\u76f8\u5173<sup>\uff3b17-18\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u56db\uff09&nbsp;\u76ae\u80a4\u5e72\u71e5\u75c7<\/h3>\n<p>\u76ae\u80a4\u5e72\u71e5\u75c7\u5728ESKD\u60a3\u8005\u4e2d\u5e38\u89c1\uff0c\u5728HD\u60a3\u8005\u4e2d\u7684\u53d1\u751f\u7387\u4e3a50%\uff5e85%\uff0c\u4ee5\u5206\u6ccc\u817a\u840e\u7f29\u548c\u57fa\u5e95\u5c42\u589e\u539a\u5bfc\u81f4\u5c40\u90e8pH\u503c\u5347\u9ad8\u548c\u89d2\u8d28\u5c42\u6c34\u5408\u4f5c\u7528\u51cf\u5c11\u4e3a\u7279\u5f81<sup>\uff3b19\uff3d<\/sup>\u3002CKD-aP\u60a3\u8005\u5c24\u5176\u662fHD\u60a3\u8005\u8868\u76ae\u6c34\u5206\u542b\u91cf\u663e\u8457\u964d\u4f4e\u3002\u7814\u7a76\u663e\u793a\uff0cHD\u60a3\u8005\u7ecf\u76ae\u6c34\u5206\u6d41\u5931\u589e\u52a0\uff0c\u8868\u660e\u5176\u5b58\u5728\u8868\u76ae\u5c4f\u969c\u53d7\u635f<sup>\uff3b19\uff3d<\/sup>\uff0c\u800cHD\u8d85\u6ee4\u5bfc\u81f4\u7684\u76ae\u80a4\u8131\u6c34\u8fdb\u4e00\u6b65\u52a0\u91cd\u76ae\u80a4\u5e72\u71e5\u3002\u4e00\u9879\u9488\u5bf95 658\u4f8b\u975e\u900f\u6790CKD 3\uff5e5\u671f\u60a3\u8005\u7684\u7814\u7a76\u663e\u793a\uff0c\u4e25\u91cd\u7619\u75d2\u75c7\u60a3\u8005\u7684\u76ae\u80a4\u5e72\u71e5\u53d1\u751f\u7387\u66f4\u9ad8<sup>\uff3b20\uff3d<\/sup>\u3002\u7136\u800c\uff0c\u4e00\u9879\u9488\u5bf9\u4f0a\u6717167\u4f8bHD\u60a3\u8005\u7684\u6a2a\u65ad\u9762\u7814\u7a76\u53d1\u73b0\uff0c\u7619\u75d2\u75c7\u548c\u65e0\u7619\u75d2\u75c7\u60a3\u8005\u4e4b\u95f4\u7684\u76ae\u80a4\u5e72\u71e5\u75c7\u60a3\u75c5\u7387\u65e0\u660e\u663e\u5dee\u5f02<sup>\uff3b19\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u4e94\uff09&nbsp;\u5176\u4ed6\u76f8\u5173\u5371\u9669\u56e0\u7d20<\/h3>\n<p>\u7ec4\u80fa\u6c34\u5e73\u5f02\u5e38\u3001\u7c7b\u80f0\u86cb\u767d\u9176\u6c34\u5e73\u5f02\u5e38\u3001\u7532\u72b6\u65c1\u817a\u529f\u80fd\u4ea2\u8fdb\u3001\u5468\u56f4\u795e\u7ecf\u75c5\u53d8\u7b49\u56e0\u7d20\u90fd\u88ab\u8bc1\u5b9e\u4e0eHD\u60a3\u8005\u7619\u75d2\u75c7\u53ca\u7619\u75d2\u75c7\u4e25\u91cd\u7a0b\u5ea6\u76f8\u5173\u3002\u7ee7\u53d1\u6027\u7532\u72b6\u65c1\u817a\u529f\u80fd\u4ea2\u8fdb\u662fHD\u60a3\u8005\u7684\u5e38\u89c1\u5e76\u53d1\u75c7\uff0c\u7814\u7a76\u8868\u660e\u5408\u5e76\u7532\u72b6\u65c1\u817a\u529f\u80fd\u4ea2\u8fdb\u60a3\u8005\u7619\u75d2\u75c7\u66f4\u4e3a\u4e25\u91cd\uff0c\u7532\u72b6\u65c1\u817a\u5207\u9664\u672f\u53ef\u7f13\u89e3\u7619\u75d2\u75c7\u72b6<sup>\uff3b21\uff3d<\/sup>\u3002CKD-aP\u60a3\u8005\u771f\u76ae\u5c42\u80a5\u5927\u7ec6\u80de\u6570\u589e\u591a\uff0c\u5176\u91ca\u653e\u7684\u7c7b\u80f0\u86cb\u767d\u9176\u548c\u7ec4\u80fa\u662f\u7619\u75d2\u75c7\u8bf1\u53d1\u5242\u3002\u7814\u7a76\u8868\u660e\uff0cCKD-aP\u60a3\u8005\u7684\u7c7b\u80f0\u86cb\u767d\u9176\u3001\u7ec4\u80fa\u548c\u55dc\u9178\u6027\u7c92\u7ec6\u80de\u6c34\u5e73\u5448\u5347\u9ad8\u8d8b\u52bf\uff0c\u4f46\u6297\u7ec4\u80fa\u836f\u6cbb\u7597CKD-aP\u6548\u679c\u5e76\u4e0d\u4ee4\u4eba\u6ee1\u610f<sup>\uff3b12\uff3d<\/sup>\uff0c\u56e0\u6b64\u7ec4\u80fa\u662f\u5426\u662fCKD-aP\u7684\u8bf1\u56e0\u5c1a\u5b58\u5728\u4e89\u8bae\u3002\u7619\u75d2\u7684\u611f\u89c9\u53ef\u80fd\u7531\u5355\u72ec\u7684\u7ec4\u80fa\u80fd\u548c\u975e\u7ec4\u80fa\u80fd\u9014\u5f84\u4f20\u9012\uff0cPapoiu\u7b49<sup>\uff3b22\uff3d<\/sup>\u7684\u7814\u7a76\u8868\u660eCKD-aP\u901a\u8fc7\u975e\u7ec4\u80fa\u80fd\u7619\u75d2\u9014\u5f84\u4f20\u9012\u3002\u6b64\u5916\uff0c\u7ef4\u751f\u7d20D\u7f3a\u4e4f\u3001\u4e19\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u90fd\u88ab\u8bc1\u5b9e\u4e0eCKD-aP\u4e25\u91cd\u7a0b\u5ea6\u76f8\u5173<sup>\uff3b23-24\uff3d<\/sup>\u3002\u7f3a\u94c1\u6027\u8d2b\u8840\u4e5f\u4e0eHD\u60a3\u8005\u7619\u75d2\u75c7\u53d1\u751f\u76f8\u5173\u3002\u4e00\u9879\u5305\u62ec73 124\u4f8b\u900f\u6790\u60a3\u8005\u7684\u7814\u7a76\u62a5\u9053\uff0c\u81ea\u6211\u62a5\u544a\u7619\u75d2\u75c7\u6700\u4e25\u91cd\u7684HD\u60a3\u8005\u6bcf\u4e2a\u6708\u9700\u8981\u4f7f\u7528\u7684\u9759\u8109\u94c1\u5242\u548c\u4fc3\u7ea2\u7ec6\u80de\u751f\u6210\u7d20\u5242\u91cf\u66f4\u591a<sup>\uff3b25\uff3d<\/sup>\u3002\u7efc\u4e0a\u6240\u8ff0\uff0cHD\u60a3\u8005\u7619\u75d2\u75c7\u7684\u53d1\u75c5\u673a\u5236\u590d\u6742\uff0c\u6d89\u53ca\u591a\u65b9\u9762\u56e0\u7d20\uff0c\u4e14\u5728\u4e0d\u540c\u7814\u7a76\u4e2d\u5b58\u5728\u4e0d\u4e00\u81f4\u7684\u7ed3\u679c\uff0c\u53ef\u80fd\u4e0e\u5176\u5e74\u9f84\u3001\u6027\u522b\u3001\u79cd\u65cf\u3001\u996e\u98df\u4e60\u60ef\u7b49\u6709\u5173\uff0c\u5176\u5177\u4f53\u7684\u53d1\u75c5\u673a\u5236\u8fd8\u6709\u5f85\u6df1\u5165\u7814\u7a76\u3002<\/p>\n<h2>\u4e09\u3001&nbsp;\u8bc4\u4f30<\/h2>\n<p>\u7619\u75d2\u662f\u4e00\u79cd\u4e3b\u89c2\u75c7\u72b6\uff0c\u5f80\u5f80\u96be\u4ee5\u91cf\u5316\u3002\u5212\u75d5\u8bd5\u9a8c\u53ef\u4ee5\u91cf\u5316\u8bc4\u4f30\uff0c\u4f46\u5728\u8bc4\u4f30\u7619\u75d2\u75c7\u4e25\u91cd\u7a0b\u5ea6\u65f6\u5f80\u5f80\u4e0d\u51c6\u786e\u3002\u76ee\u524d\uff0c\u901a\u5e38\u91c7\u7528\u60a3\u8005\u62a5\u544a\u7ed3\u679c\u6765\u8bc4\u4f30\u7619\u75d2\u75c7<sup>\uff3b26\uff3d<\/sup>\u3002\u6709\u591a\u79cd\u91cf\u8868\u53ef\u7528\u4e8e\u8bc4\u4f30\u7619\u75d2\u75c7\u7a0b\u5ea6\uff0c\u5305\u62ec\u8bc4\u4f30\u5355\u4e00\u75c7\u72b6\u7684\u5355\u7ef4\u91cf\u8868\u548c\u8bc4\u4f30\u591a\u79cd\u75c7\u72b6\u548c\u75c7\u72b6\u53d8\u5316\u7684\u591a\u7ef4\u91cf\u8868\u3002\u89c6\u89c9\u6a21\u62df\u91cf\u8868\uff08visual analog scale\uff0cVAS\uff09\u3001\u6570\u5b57\u8bc4\u5206\u91cf\u8868\uff08numeric rating scale\uff0cNRS\uff09\u3001\u8bed\u8a00\u8bc4\u5206\u91cf\u8868\uff08verbal rating scale\uff0cVRS\uff09\u662f\u4e00\u7ef4\u91cf\u8868\uff0c\u7528\u4e8e\u8bc4\u4f30\u7619\u75d2\u75c7\u7684\u4e25\u91cd\u7a0b\u5ea6\u3002VAS\u4f7f\u7528\u89c6\u89c9\u6216\u56fe\u5f62\u91cf\u8868\uff0c\u8981\u6c42\u60a3\u8005\u9009\u62e9\u4e00\u4e2a\u70b9\u6765\u63cf\u8ff0\u5176\u75c7\u72b6\u7684\u4e25\u91cd\u7a0b\u5ea6\uff0c0\u8868\u793a\u4e0d\u75d2\uff0c10\u8868\u793a\u7619\u75d2\u75c7\u6700\u4e25\u91cd\u3002NRS\u4e0eVAS\u7c7b\u4f3c\uff0c\u8981\u6c42\u60a3\u8005\u9009\u62e90\uff5e10\u5206\u4e4b\u95f4\u7684\u6570\u503c\uff0c\u5c06\u7619\u75d2\u75c7\u4e25\u91cd\u7a0b\u5ea6\u5206\u4e3a\u65e0\uff080\u5206\uff09\u3001\u8f7b\u5ea6\uff081\uff5e3\u5206\uff09\u3001\u4e2d\u5ea6\uff084\uff5e6\u5206\uff09\u3001\u4e25\u91cd\uff087\uff5e8\u5206\uff09\u548c\u975e\u5e38\u4e25\u91cd\uff08\u22659\u5206\uff09\u3002\u5e38\u7528\u7684\u591a\u7ef4\u7619\u75d2\u75c7\u91cf\u8868\u67095-D\u7619\u75d2\u75c7\u91cf\u8868\u548c\u80be\u810f\u75be\u75c5\u751f\u6d3b\u8d28\u91cf\u77ed\u8868\uff08Kidney Disease Quality of Life-Short Form\uff0cKDQOL-SF\uff09\u30025-D\u7619\u75d2\u75c7\u91cf\u8868\u8bc4\u4f30\u4e86\u7619\u75d2\u75c7\u7a0b\u5ea6\u3001\u6301\u7eed\u65f6\u95f4\u3001\u6a21\u5f0f\u53ca\u5176\u5bf9\u751f\u6d3b\u8d28\u91cf\u7684\u5f71\u54cd\uff0c\u800cKDQOL-SF\u4e3b\u8981\u8bc4\u4ef7\u7619\u75d2\u75c7\u5bf9\u751f\u6d3b\u8d28\u91cf\u7684\u5f71\u54cd\u3002<\/p>\n<h2>\u56db\u3001&nbsp;\u6cbb\u7597\u8fdb\u5c55<\/h2>\n<p>CKD-aP\u6cbb\u7597\u7387\u4f4e\u4e0e\u60a3\u8005\u77e5\u6653\u7387\u4f4e\u3001\u62a5\u544a\u4e0d\u8db3\u548c\u533b\u52a1\u4eba\u5458\u5bf9\u75be\u75c5\u7684\u8ba4\u8bc6\u4e0d\u8db3\u76f8\u5173\u3002DOPPS 5\u671f\u7814\u7a76<sup>\uff3b4\uff3d<\/sup>\u663e\u793a\uff0c17% CKD-aP\u60a3\u8005\u672a\u5411\u533b\u52a1\u4eba\u5458\u62a5\u544a\u7619\u75d2\u75c7\uff0c69%\u533b\u5e08\u4f4e\u4f30\u4e86\u6240\u5728\u900f\u6790\u4e2d\u5fc3CKD-aP\u7684\u60a3\u75c5\u7387\u3002\u603b\u4f53\u6cbb\u7597\u539f\u5219\u5e94\u5728\u786e\u8ba4\u60a3\u8005\u7684\u5e74\u9f84\u3001\u65e2\u5f80\u75be\u75c5\u3001\u4f7f\u7528\u836f\u7269\u4ee5\u53ca\u6162\u6027\u7619\u75d2\u75c7\u7684\u9891\u7387\u548c\u7a0b\u5ea6\u540e\uff0c\u5408\u7406\u89c4\u5212\u8fdb\u884c\u4e2a\u4f53\u5316\u6cbb\u7597\uff0c\u5e76\u4e14\u9700\u8981\u907f\u514d\u6240\u6709\u5bfc\u81f4\u7619\u75d2\u75c7\u52a0\u91cd\u7684\u56e0\u7d20\uff0c\u5982\u8fc7\u654f\u548c\u523a\u6fc0\u6027\u7269\u8d28\u3001\u538b\u529b\u3001\u4e59\u9187\u6216\u8f9b\u8fa3\u98df\u7269\u3002\u9488\u5bf9HD\u60a3\u8005\u7619\u75d2\u75c7\u7684\u57fa\u672c\u6cbb\u7597\u65b9\u5f0f\u4e3b\u8981\u5305\u62ec\u836f\u7269\u6cbb\u7597\u3001\u975e\u836f\u7269\u6cbb\u7597\u548c\u900f\u6790\u65b9\u5f0f\u6539\u53d8\u3002<\/p>\n<h3>\uff08\u4e00\uff09&nbsp;\u836f\u7269\u6cbb\u7597<\/h3>\n<p>1. \u7cfb\u7edf\u6027\u7528\u836f\uff1a\uff081\uff09\u6297\u766b\u75eb\u7c7b\u836f\u7269\uff1a\u52a0\u5df4\u55b7\u4e01\u548c\u666e\u745e\u5df4\u6797\u662f\u76ee\u524dCKD-aP\u6cbb\u7597\u8ba4\u53ef\u5ea6\u8f83\u9ad8\u7684\u836f\u7269\uff0c\u4f5c\u4e3a\u03b3-\u6c28\u57fa\u4e01\u9178\u76f8\u5173\u7684\u6297\u60ca\u53a5\u836f\uff0c\u901a\u8fc7\u4f5c\u7528\u4e8e\u7535\u538b\u4f9d\u8d56\u6027\u9499\u79bb\u5b50\u901a\u9053\u6539\u53d8\u5bf9\u7619\u75d2\u75c7\u4ea7\u751f\u7684\u81f3\u5173\u91cd\u8981\u7684\u795e\u7ecf\u51b2\u52a8\u3002\u52a0\u5df4\u55b7\u4e01\u4e3b\u8981\u901a\u8fc7\u80be\u810f\u6e05\u9664\uff0cHD\u4e5f\u53ef\u6e05\u9664\u836f\u7269\u3002\u4e0e\u80be\u529f\u80fd\u6b63\u5e38\u60a3\u8005\u76f8\u6bd4\uff0c\u52a0\u5df4\u55b7\u4e01\u5728HD\u60a3\u8005\u7684\u534a\u8870\u671f\u660e\u663e\u5ef6\u957f\uff0c\u56e0\u6b64\u5728HD\u60a3\u8005\u4e2d\u4f7f\u7528\u52a0\u5df4\u55b7\u4e01\u9700\u964d\u4f4e\u5242\u91cf\u3001\u5ef6\u957f\u7528\u836f\u95f4\u9694\uff0c\u63a8\u8350\u5242\u91cf\u4e3a\u900f\u6790\u540e200\uff5e300 mg\u30022004\u5e74\uff0cGunal\u7b49<sup>\uff3b27\uff3d<\/sup>\u8fdb\u884c\u7684\u9996\u9879\u5173\u4e8e\u52a0\u5df4\u55b7\u4e01\u7528\u4e8eCKD-aP\u7684\u5b89\u6170\u5242\u5bf9\u7167\u4e34\u5e8a\u8bd5\u9a8c\u663e\u793a\uff0c\u900f\u6790\u6cbb\u7597\u540e\u53e3\u670d\u52a0\u5df4\u55b7\u4e01\uff08300 mg\uff0c\u6bcf\u54683\u6b21\uff09\u53ef\u6709\u6548\u63a7\u5236\u7619\u75d2\u75c7\uff0c\u5176\u4e2d\u90e8\u5206\u60a3\u8005\u7684\u7619\u75d2\u75c7\u53ef\u5b8c\u5168\u7f13\u89e3\u3002\u672c\u8bfe\u9898\u7ec4\u57282010\u5e74\u8fdb\u884c\u7684\u5c0f\u89c4\u6a21\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\u7814\u7a76\u663e\u793a\uff0c\u76f8\u6bd4\u53e3\u670d\u6c2f\u96f7\u4ed6\u5b9a\uff0c\u900f\u6790\u540e\u53e3\u670d\u52a0\u5df4\u55b7\u4e0112\u5468\u53ef\u4f7fHD\u60a3\u8005\u7619\u75d2\u75c7\u53ca\u7761\u7720\u660e\u663e\u6539\u5584<sup>\uff3b28\uff3d<\/sup>\u3002\u670d\u7528\u52a0\u5df4\u55b7\u4e01\u60a3\u8005\u4e2d\uff0c36%\uff089\/25\uff09\u51fa\u73b0\u55dc\u7761\uff0c\u4f46\u75c7\u72b6\u5747\u57281\u5468\u5185\u51cf\u8f7b\u6216\u6d88\u5931<sup>\uff3b28\uff3d<\/sup>\u3002\u9274\u4e8e\u52a0\u5df4\u55b7\u4e01\u5e38\u89c1\u7684\u4e0d\u826f\u53cd\u5e94\uff0c\u5efa\u8bae\u5728\u6297\u7ec4\u80fa\u836f\u548c\/\u6216\u5c40\u90e8\u6da6\u80a4\u5242\u65e0\u6548\u7684\u60c5\u51b5\u4e0b\uff0c\u5728\u900f\u6790\u540e\u5c3d\u53ef\u80fd\u4f7f\u7528\u4f4e\u7684\u8d77\u59cb\u53e3\u670d\u5242\u91cf\uff0c\u5982100 mg\u5f00\u59cb\u4f7f\u7528\u3002\u5bf9\u4e8e\u52a0\u5df4\u55b7\u4e01\u4e0d\u8010\u53d7\u7684\u60a3\u8005\uff0c\u53ef\u4f7f\u7528\u666e\u745e\u5df4\u6797\u3002Rayner\u7b49<sup>\uff3b29\uff3d<\/sup>\u7684\u4e00\u9879\u89c2\u5bdf\u6027\u7814\u7a76\u5bf9\u52a0\u5df4\u55b7\u4e01\u4e0d\u80fd\u8010\u53d7\u7684CKD-aP\u60a3\u8005\u6539\u7528\u666e\u745e\u5df4\u6797\uff0c\u5728\u672a\u63a5\u53d7\u900f\u6790\u548c\u63a5\u53d7\u900f\u6790\u60a3\u8005\u4e2d\u5747\u53ef\u8fbe\u5230\u663e\u8457\u7f13\u89e3\u7619\u75d2\u75c7\u7684\u6548\u679c\u3002\uff082\uff09\u963f\u7247\u7c7b\u53d7\u4f53\u6fc0\u52a8\u5242\/\u62ee\u6297\u5242\uff1a\u5927\u91cf\u8bd5\u9a8c\u548c\u4e34\u5e8a\u89c2\u5bdf\u7814\u7a76\u8bc1\u5b9e\u4e86\u963f\u7247\u53d7\u4f53\u5728\u6162\u6027\u7619\u75d2\u75c7\u548cHD\u60a3\u8005\u7619\u75d2\u75c7\u4e2d\u7684\u4f5c\u7528\u3002\u8fd1\u671f\u4e00\u9879\u591a\u4e2d\u5fc3\u968f\u673a\u5bf9\u7167\u7814\u7a76<sup>\uff3b30\uff3d<\/sup>\u663e\u793a\uff0cMOR\u62ee\u6297\u5242\u53caKOR\u6fc0\u52a8\u5242\u2014\u2014\u7eb3\u5e03\u5561\uff08nalbuphine\uff09120 mg\u53ef\u663e\u8457\u7f13\u89e3HD\u60a3\u8005\u7684\u4e2d\u91cd\u5ea6\u7619\u75d2\u75c7\u3002\u7136\u800c\uff0c\u65e9\u671f\u5173\u4e8eMOR\u62ee\u6297\u5242\u7eb3\u66f2\u916e\uff08naltrexone\uff09\u5728CKD-aP\u4e2d\u8fdb\u884c\u7684\u5bf9\u7167\u7814\u7a76\u663e\u793a\u51fa\u4e0d\u4e00\u81f4\u7684\u7ed3\u679c\u30021996\u5e74\u53d1\u8868\u4e8e\u67f3\u53f6\u5200\u6742\u5fd7\u7684\u7814\u7a76\u8868\u660e\u7eb3\u66f2\u916e\u77ed\u671f\u5185\u53ef\u663e\u8457\u7f13\u89e3\u900f\u6790\u60a3\u8005\u4e25\u91cd\u96be\u6cbb\u7684\u7619\u75d2\u75c7<sup>\uff3b31\uff3d<\/sup>\uff0c\u800c2000\u5e74\u53ca2004\u5e74\u76842\u9879\u7814\u7a76\u5374\u663e\u793a\u7eb3\u66f2\u916e\u5bf9CKD-aP\u60a3\u8005\u7684\u7619\u75d2\u75c7\u65e0\u660e\u663e\u6539\u5584\u4f5c\u7528<sup>\uff3b32\uff3d<\/sup>\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u8fd1\u671f\u4e00\u9879\u7814\u7a76\u5bf9\u900f\u6790\u60a3\u8005\u76ae\u80a4\u4e2dMOR\u53caKOR\u7684\u8868\u8fbe\u60c5\u51b5\u8fdb\u884c\u4e86\u5206\u6790\uff0c\u7ed3\u679c\u8868\u660e\uff0c\u65e0\u7619\u75d2\u75c7\u7684\u900f\u6790\u60a3\u8005KOR\u7684\u8868\u8fbe\u663e\u8457\u4f4e\u4e8e\u5408\u5e76\u7619\u75d2\u75c7\u7684\u900f\u6790\u60a3\u8005\uff0c\u4e14KOR\u7684\u8868\u8fbe\u60c5\u51b5\u4e0e\u7619\u75d2\u75c7\u7a0b\u5ea6\u5448\u8d1f\u76f8\u5173\u3002\u7136\u800c\uff0cMOR\u5728\u4e24\u7ec4\u60a3\u8005\u7684\u8868\u8fbe\u5374\u65e0\u663e\u8457\u5dee\u5f02<sup>\uff3b33\uff3d<\/sup>\u3002\u6b64\u5916\uff0c\u6709\u591a\u9879\u7814\u7a76\u8868\u660e\uff0cMOR\u62ee\u6297\u5242\u5728\u6cbb\u7597CKD-aP\u65f6\u4f1a\u4ea7\u751f\u660e\u663e\u7684\u4e0d\u826f\u53cd\u5e94\uff0c\u5982\u6076\u5fc3\u3001\u5455\u5410\u3001\u8179\u6cfb\u7b49\u80c3\u80a0\u9053\u75c7\u72b6\uff0c\u5934\u6655\u3001\u9ad8\u8840\u538b\u6216\u4f4e\u8840\u538b\u7b49\u5fc3\u8840\u7ba1\u75c7\u72b6\uff0c\u4ee5\u53ca\u75b2\u4e4f\u3001\u5934\u75db\u7b49\u795e\u7ecf\u7cfb\u7edf\u75c7\u72b6<sup>\uff3b30\uff0c32\uff3d<\/sup>\u3002\u6709\u7814\u7a76\u6307\u51fa\uff0c\u76f8\u6bd4CKD-aP\uff0cMOR\u62ee\u6297\u5242\u66f4\u9002\u7528\u4e8e\u80c6\u6c41\u6de4\u79ef\u76f8\u5173\u7619\u75d2\u75c7\u7684\u4e8c\u7ebf\u6cbb\u7597<sup>\uff3b34\uff3d<\/sup>\u3002\u4e0eMOR\u62ee\u6297\u5242\u76f8\u6bd4\uff0cKOR\u6fc0\u52a8\u5242\u4e0d\u826f\u53cd\u5e94\u8f83\u5c11\uff0c\u4e14\u5177\u6709\u4e0d\u4f1a\u4fc3\u8fdb\u6b23\u5feb\u611f\u3001\u6210\u763e\u6027\u5c0f\u7684\u7279\u70b9\u3002\u76d0\u9178\u7eb3\u544b\u62c9\u5561\u662f\u4e00\u79cd\u9ad8\u9009\u62e9\u6027KOR\u6fc0\u52a8\u5242\uff0c\u5728\u9547\u75db\u540c\u65f6\uff0c\u8fd8\u53ef\u6709\u6548\u6291\u5236P\u7269\u8d28\u548c\u7ec4\u80fa\u5f15\u8d77\u7684\u7619\u75d2\u75c7\uff0c\u4e8e2009\u5e74\u5728\u65e5\u672c\u83b7\u6279\uff0c\u7528\u4e8e\u6539\u5584\u73b0\u6709\u6cbb\u7597\u6548\u679c\u4e0d\u7406\u60f3\u7684\u900f\u6790\u60a3\u8005\u3001\u6162\u6027\u809d\u75c5\u60a3\u8005\u7684\u7619\u75d2\u75c7\u3002\u4e24\u9879\u5927\u578b\u968f\u673a\u5bf9\u7167\u7814\u7a76\u663e\u793a\uff0c\u76d0\u9178\u7eb3\u544b\u62c9\u5561\u5bf9CKD-aP\u60a3\u8005\u6cbb\u7597\u524d7 d\u7684\u75c7\u72b6\u5177\u6709\u663e\u8457\u7684\u4e34\u5e8a\u7597\u6548<sup>\uff3b35-36\uff3d<\/sup>\u3002\u4e00\u9879\u4e3a\u671f52\u5468\u7684\u4e34\u5e8a\u7814\u7a76\u663e\u793a\uff0c\u5bf9\u4e8e\u73b0\u6709\u6cbb\u7597\u62b5\u6297\u7684HD\u60a3\u8005\u7619\u75d2\u75c7\uff0c\u957f\u671f\u4f7f\u7528\u76d0\u9178\u7eb3\u544b\u62c9\u5561\uff085 \u03bcg\/d\uff09\u5b89\u5168\u6709\u6548\uff0c\u6ca1\u6709\u4ea7\u751f\u8eaf\u4f53\u4f9d\u8d56\u548c\u7cbe\u795e\u4f9d\u8d56\uff0c\u65e0\u6210\u763e\u98ce\u9669<sup>\uff3b37\uff3d<\/sup>\u3002\u4e2d\u56fd\u2162\u671f\u4e34\u5e8a\u6865\u63a5\u8bd5\u9a8c\uff08SYSS-Remitch-HD-\u2162-01\/5.3.5.1-4\uff09\u663e\u793a\uff0c\u4f7f\u7528\u76d0\u9178\u7eb3\u544b\u62c9\u55615 \u00b5g\/d\u62162.5 \u00b5g\/d\uff0c\u8fde\u7eed\u7528\u836f14 d\uff0c\u5747\u80fd\u6539\u5584HD\u60a3\u8005\u96be\u6cbb\u6027\u7619\u75d2\u75c7\uff0c\u4e0e\u65e5\u672c\u9a8c\u8bc1\u6027\u2162\u671f\u8bd5\u9a8c\u7ed3\u679c\u4e00\u81f4<sup>\uff3b36\uff0c38\uff3d<\/sup>\u3002\u636e\u62a5\u9053\uff0c\u7619\u75d2\u75c7\u662fHD\u60a3\u8005\u6291\u90c1\u7684\u5371\u9669\u56e0\u7d20\uff0c\u76d0\u9178\u7eb3\u544b\u62c9\u5561\u4e0d\u4ec5\u53ef\u4ee5\u6539\u5584\u5176\u7619\u75d2\u75c7\uff0c\u8fd8\u53ef\u4ee5\u6539\u5584\u5176\u7cbe\u795e\u72b6\u51b5<sup>\uff3b39\uff3d<\/sup>\u3002\u6b64\u5916\uff0c2021\u5e748\u6708\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u4e86\u4e00\u79cd\u5916\u5468\u9650\u5236\u6027\u548c\u9009\u62e9\u6027\u7684KOR\u6fc0\u52a8\u5242Difelikefalin\uff0c\u7528\u4e8e\u6cbb\u7597HD\u60a3\u8005\u7684\u7619\u75d2\u75c7\uff08NDA214916\uff09\uff0c\u5176\u901a\u8fc7\u523a\u6fc0\u5916\u5468\u795e\u7ecf\u548c\u514d\u75ab\u7ec6\u80de\u4e0a\u7684KOR\u53d1\u6325\u6b62\u75d2\u7684\u4f5c\u7528\u3002\uff083\uff09\u5176\u4ed6\u836f\u7269\uff1a\u6297\u7ec4\u80fa\u836f\u662f\u6cbb\u7597\u6162\u6027\u7619\u75d2\u75c7\u7684\u5e38\u7528\u836f\u7269\u3002\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u53ef\u5206\u4e3a\u7ec4\u80fa\u53d7\u4f53\u62ee\u6297\u5242\uff0c\u5982\u82ef\u6d77\u62c9\u660e\u3001\u7f9f\u55ea\u3001\u6c2f\u96f7\u4ed6\u5b9a\u6216\u897f\u66ff\u5229\u55ea\uff0c\u4ee5\u53ca\u80a5\u5927\u7ec6\u80de\u7a33\u5b9a\u5242\uff0c\u5982\u8272\u7518\u9178\u94a0\u3001\u786b\u9178\u950c\u548c\u916e\u66ff\u82ac\u3002\u7136\u800c\uff0c\u7ec4\u80fa\u53d7\u4f53\u62ee\u6297\u5242\u5728HD\u60a3\u8005\u7619\u75d2\u75c7\u6cbb\u7597\u7684\u7814\u7a76\u672a\u83b7\u5f97\u6210\u529f<sup>\uff3b40\uff3d<\/sup>\u3002\u80a5\u5927\u7ec6\u80de\u7a33\u5b9a\u5242\u5728\u6cbb\u7597CKD-aP\u65b9\u9762\u6709\u79ef\u6781\u7684\u6548\u679c\u3002\u5728\u4e00\u9879\u5bf960\u4f8bHD\u60a3\u8005\u8fdb\u884c\u4e3a\u671f4\u5468\u7684\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\u4e2d\uff0c\u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\uff0c4%\u8272\u7518\u9178\u94a0\u4e73\u818f\u660e\u663e\u964d\u4f4e\u7619\u75d2\u75c7\u7684\u4e25\u91cd\u7a0b\u5ea6<sup>\uff3b41\uff3d<\/sup>\u3002\u5728\u4e00\u9879\u5bf940\u4f8bHD\u60a3\u8005\u8fdb\u884c\u4e3a\u671f2\u4e2a\u6708\u7684\u53cc\u76f2\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\u4e2d\uff0c\u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\uff0c\u786b\u9178\u950c\u660e\u663e\u6539\u5584\u7619\u75d2\u75c7<sup>\uff3b41\uff3d<\/sup>\uff1b\u7136\u800c\uff0c\u4e5f\u6709\u7814\u7a76\u663e\u793a\u80a5\u5927\u7ec6\u80de\u7a33\u5b9a\u5242\u5bf9\u6cbb\u7597CKD-aP\u65e0\u6548<sup>\uff3b42\uff3d<\/sup>\u3002\u6b64\u5916\uff0c\u7814\u7a76\u53d1\u73b0\u53e3\u670d\u6d3b\u6027\u70ad\u53ef\u80fd\u901a\u8fc7\u5438\u6536\u548c\u6539\u53d8\u80a0\u9053\u5fae\u751f\u7269\u8054\u5408\u53d1\u6325\u4f5c\u7528\uff0c\u6539\u5584HD\u60a3\u8005\u7684\u7619\u75d2\u75c7\u548c\u4ee3\u8c22\u72b6\u6001<sup>\uff3b43\uff3d<\/sup>\u3002\u6709\u62a5\u9053\u663e\u793a\u6297\u6291\u90c1\u836f\u7269\u9009\u62e9\u60275-\u7f9f\u8272\u80fa\u518d\u6444\u53d6\u6291\u5236\u5242\u820d\u66f2\u6797\u6cbb\u75974\u5468\u53ef\u4ee5\u660e\u663e\u6539\u5584HD\u60a3\u8005\u7684\u7619\u75d2\u75c7<sup>\uff3b44\uff3d<\/sup>\u3002\u767d\u4e09\u70ef\u53ef\u80fd\u5728\u708e\u75c7\u4ecb\u5bfc\u7684\u5c3f\u6bd2\u75c7\u6027\u7619\u75d2\u75c7\u4e2d\u8d77\u4f5c\u7528\uff0c\u6709\u5c0f\u578b\u968f\u673a\u5bf9\u7167\u7814\u7a76\u663e\u793a\u767d\u4e09\u70ef\u53d7\u4f53\u62ee\u6297\u5242\u5b5f\u9c81\u53f8\u7279\u80fd\u591f\u663e\u8457\u6539\u5584\u7619\u75d2\u75c7<sup>\uff3b45\uff3d<\/sup>\u30022. \u5c40\u90e8\u7528\u836f\uff1a\u8db3\u91cf\u4f7f\u7528\u542b\u6c34\u91cf\u9ad8\u7684\u6da6\u80a4\u5242\u53ef\u8f85\u52a9\u6062\u590dCKD-aP\u60a3\u8005\u7684\u76ae\u80a4\u5c4f\u969c\u5e76\u4fdd\u7559\u89d2\u8d28\u5c42\u4e2d\u7684\u6c34\u5206\uff0c\u4ee5\u7f13\u89e3\u76ae\u80a4\u5e72\u71e5\u75c7\u8fdb\u800c\u51cf\u8f7b\u7619\u75d2\u75c7\u3002\u5c40\u90e8\u9547\u75db\u836f\u5982\u666e\u62c9\u83ab\u8f9b\u548c\u8fa3\u6912\u7d20\u4e5f\u53ef\u7528\u4e8e\u6539\u5584CKD-aP\uff0c\u8fd9\u4e24\u79cd\u5316\u5408\u7269\u901a\u8fc7\u963b\u65ad\u6765\u81ea\u76ae\u80a4\u7684\u795e\u7ecf\u51b2\u52a8\uff0c\u5bfc\u81f4\u611f\u89c9\u51cf\u9000\u548c\u9ebb\u6728\uff0c\u4ece\u800c\u8fbe\u5230\u7f13\u89e3\u7619\u75d2\u75c7\u7684\u4f5c\u7528\u3002\u4e00\u9879\u5305\u62ec28\u4f8b\u60a3\u8005\u7684\u5355\u81c2\u5e73\u884c\u7814\u7a76\u53d1\u73b0\uff0c\u4e0e\u5355\u72ec\u4f7f\u7528\u6da6\u80a4\u5242\u76f8\u6bd4\uff0c\u6bcf\u59292\u6b21\u4f7f\u7528\u666e\u62c9\u83ab\u8f9b\u53ef\u663e\u8457\u7f13\u89e3HD\u60a3\u8005\u7684\u7619\u75d2\u75c7<sup>\uff3b46\uff3d<\/sup>\u3002\u542b\u6709\u666e\u62c9\u83ab\u8f9b\u7684\u6da6\u80a4\u5242\u4e5f\u53ef\u4ee5\u4f5c\u4e3aHD\u60a3\u8005\u53ef\u9009\u62e9\u7684\u5c40\u90e8\u6cbb\u7597\u65b9\u5f0f\u3002\u5404\u79cd\u7814\u7a76\u8868\u660e\uff0c\u8fa3\u6912\u7d20\u4e5f\u53ef\u6709\u6548\u51cf\u8f7b\u4f34\u6709\u5c40\u90e8\u7619\u75d2\u75c7HD\u60a3\u8005\u7684\u7619\u75d2\u75c7\u72b6<sup>\uff3b47\uff3d<\/sup>\uff0c\u7136\u800c\uff0c\u76ee\u524d\u4ecd\u7136\u7f3a\u4e4f\u8bc4\u4f30\u5176\u6709\u6548\u6027\u7684\u5bf9\u7167\u8bd5\u9a8c\u6570\u636e\u3002\u6b64\u5916\uff0cL-\u7cbe\u6c28\u9178\u8f6f\u818f\u5df2\u88ab\u8bc1\u660e\u53ef\u6539\u5584\u76ae\u80a4\u5e72\u71e5\uff0c\u5c24\u5176\u662f\u6539\u5584HD\u60a3\u8005\u7684\u7619\u75d2\u75c7<sup>\uff3b48\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u4e8c\uff09&nbsp;\u975e\u836f\u7269\u6cbb\u7597<\/h3>\n<p>Tseng\u7b49<sup>\uff3b49\uff3d<\/sup>\u53d1\u73b0\u7d20\u98df\u6709\u52a9\u4e8e\u6539\u5584CKD-aP\u60a3\u8005\u7684\u7619\u75d2\u75c7\u3002\u7d20\u98df\u8005\u7684VAS\u8bc4\u5206\u53ca\u708e\u75c7\u6307\u6807\u5305\u62ec\u8d85\u654fC\u53cd\u5e94\u86cb\u767d\u548cIL-2\u6c34\u5e73\u5747\u663e\u8457\u4f4e\u4e8e\u975e\u7d20\u98df\u8005\uff0c\u6709\u8da3\u7684\u662f\uff0c\u63a5\u53d76\u4e2a\u6708\u975e\u7d20\u98df\u7684\u60a3\u8005\u5728\u6539\u4e3a\u7d20\u98df2\u4e2a\u6708\u540e\uff0c\u5176\u708e\u75c7\u6307\u6807\u660e\u663e\u6539\u5584\u3002\u5728\u81b3\u98df\u4e2d\u8865\u5145\u03c9-3\u8102\u80aa\u9178\u53ef\u80fd\u901a\u8fc7\u964d\u4f4e\u8102\u6c27\u5408\u9176\u9014\u5f84\u7684\u6d3b\u6027\u8fdb\u800c\u53d1\u6325\u6297\u708e\u4f5c\u7528\uff0c\u4ece\u800c\u6539\u5584CKD-aP\u60a3\u8005\u7684\u7619\u75d2\u75c7<sup>\uff3b50\uff3d<\/sup>\u3002\u7d2b\u5916\u7ebf\u5149\u7597\u5e7f\u6cdb\u7528\u4e8e\u6cbb\u7597\u5404\u79cd\u76ae\u80a4\u75c5\uff0c\u5149\u7597\u6709\u6548\u6027\u7684\u673a\u5236\u5305\u62ec\u6291\u5236\u6717\u683c\u6c49\u65af\u7ec6\u80de\u3001\u964d\u4f4e\u4fc3\u708e\u7ec6\u80de\u56e0\u5b50\u6c34\u5e73\u3001\u52a0\u5f3a\u76ae\u80a4\u5c4f\u969c\u3001\u5347\u9ad8\u8840\u6e0525-\u7f9f\u57fa\u7ef4\u751f\u7d20D3\u6c34\u5e73\u53ca\u8bf1\u5bfc\u80a5\u5927\u7ec6\u80de\u51cb\u4ea1\u3002\u5149\u7597\u5728CKD-aP\u4e2d\u7684\u5e94\u7528\u572820\u4e16\u7eaa70\u5e74\u4ee3\u9996\u6b21\u88ab\u63d0\u53ca\uff0c\u4e4b\u540e\u8bb8\u591a\u7814\u7a76\u663e\u793a\u4e86\u5b9e\u65bd\u5bbd\u8c31\u7d2b\u5916\u7ebf\u5149\u7597\u7684\u6709\u6548\u6027<sup>\uff3b51\uff3d<\/sup>\u3002\u6b64\u5916\uff0c\u4e5f\u6709\u7814\u7a76\u8bc1\u660e\u7a84\u8c31\u7d2b\u5916\u7ebf\u5149\u7597\u53ef\u6709\u6548\u6cbb\u7597\u900f\u6790\u60a3\u8005\u7684\u6162\u6027\u7619\u75d2\u75c7<sup>\uff3b52\uff3d<\/sup>\u3002\u7531\u4e8e\u897f\u533b\u6cbb\u7597\u5728\u7f13\u89e3CKD-aP\u60a3\u8005\u7619\u75d2\u75c7\u7684\u6548\u679c\u6709\u9650\uff0c\u4e2d\u533b\u6cbb\u7597\u7b56\u7565\u4e5f\u9010\u6e10\u53d7\u5230\u91cd\u89c6\u3002\u76ee\u524d\u5e38\u7528\u4e8e\u6cbb\u7597CKD-aP\u7684\u4e2d\u533b\u6cbb\u7597\u65b9\u5f0f\u5305\u62ec\u9488\u7078\u3001\u7a74\u4f4d\u6309\u538b\u7b49\uff0c\u867d\u7136\u9488\u7078\u5bf9\u7619\u75d2\u75c7\u7684\u4f5c\u7528\u673a\u5236\u5c1a\u4e0d\u6e05\u695a\uff0c\u4f46\u636e\u63a8\u6d4b\uff0c\u5b83\u662f\u901a\u8fc7\u526f\u4ea4\u611f\u795e\u7ecf\u652f\u914d\u548c\u58f3\u6838-\u540e\u6263\u5e26\u76ae\u5c42\u7684\u6b63\u529f\u80fd\u8fde\u63a5\u8d77\u4f5c\u7528\u3002\u6709\u7814\u7a76\u572875\u4f8bCKD-aP\u60a3\u8005\u4e2d\u5206\u6790LI-11\u70b9\u7a74\u4f4d\u6309\u6469\u4e0e\u7ecf\u76ae\u7a74\u4f4d\u7535\u523a\u6fc0\u7684\u6548\u679c\uff0c\u7ed3\u679c\u53d1\u73b0\uff0c\u7a74\u4f4d\u6309\u6469\u548c\u7ecf\u76ae\u7a74\u4f4d\u7535\u523a\u6fc0\u5728\u7f13\u89e3\u7619\u75d2\u75c7\u65b9\u9762\u6bd4\u5bf9\u7167\u7ec4\u66f4\u6709\u6548<sup>\uff3b53\uff3d<\/sup>\u3002\u53e6\u4e00\u9879\u7814\u7a76\u53d1\u73b0\uff08n=62\uff09\uff0c\u76f8\u6bd4\u5bf9\u7167\u7ec4\uff0c\u8033\u7a74\u8d34\u8c46\u7ec4\u80fd\u663e\u8457\u964d\u4f4eHD\u60a3\u8005\u7684\u7619\u75d2\u75c7\u7a0b\u5ea6<sup>\uff3b54\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u4e09\uff09&nbsp;\u8c03\u6574\u900f\u6790\u65b9\u5f0f<\/h3>\n<p>\u900f\u6790\u5242\u91cf\u5bf9\u7619\u75d2\u75c7\u7684\u5f71\u54cd\u76ee\u524d\u5c1a\u65e0\u5b9a\u8bba\u30021995\u5e74\u5f00\u5c55\u7684\u4e00\u9879\u4e3a\u671f12\u4e2a\u6708\u7684\u524d\u77bb\u6027\u7814\u7a76\u663e\u793a\uff0c\u900f\u6790\u5145\u5206\u6027\u4e0e\u7619\u75d2\u75c7\u7684\u4e25\u91cd\u7a0b\u5ea6\u5448\u8d1f\u76f8\u5173\uff0c\u589e\u52a0\u900f\u6790\u5242\u91cf\u53ef\u51cf\u8f7b\u60a3\u8005\u7619\u75d2\u75c7\uff0c\u4f46\u8fd9\u9879\u7814\u7a76\u7684\u6574\u4f53\u5c3f\u7d20\u6e05\u9664\u6307\u6570\uff08Kt\/V\uff09\u6c34\u5e73\u8f83\u4f4e\uff0c\u65e0\u7619\u75d2\u75c7\u60a3\u8005\u3001\u7619\u75d2\u75c7\u57283\u4e2a\u6708\u5185\u51cf\u8f7b\u60a3\u8005\u4ee5\u53ca\u957f\u671f\u4e25\u91cd\u7619\u75d2\u75c7\u60a3\u8005\u7684\u5e73\u5747Kt\/V\u5206\u522b\u4e3a1.31\u30011.28\u548c1.09<sup>\uff3b55\uff3d<\/sup>\u3002\u53e6\u4e00\u9879\u7eb3\u5165111\u4f8bHD\u60a3\u8005\u7684\u7814\u7a76\u53d1\u73b0\uff0cKt\/V&lt;1.5\u7684\u60a3\u8005\u66f4\u5bb9\u6613\u51fa\u73b0\u7619\u75d2\uff0c\u800cKt\/V&gt;1.5\u7684\u60a3\u8005\u5219\u4e0d\u5bb9\u6613\u51fa\u73b0\u7619\u75d2\u75c7<sup>\uff3b56\uff3d<\/sup>\u3002\u7136\u800c\uff0c\u5728\u53e6\u4e00\u9879\u5305\u542b105\u4f8b\u60a3\u8005\u7684\u961f\u5217\u7814\u7a76\u4e2d\uff0c\u65e0\u7619\u75d2\u75c7\u60a3\u8005\u7684\u5e73\u5747Kt\/V\u4e3a1.7\uff0c\u6709\u7619\u75d2\u75c7\u60a3\u8005\u7684\u5e73\u5747Kt\/V\u4e3a1.82<sup>\uff3b57\uff3d<\/sup>\u3002\u4f5c\u8005\u8ba4\u4e3a\u5728\u6b8b\u4f59\u80be\u529f\u80fd\u8f83\u5dee\u6216\u4ee3\u8c22\u6bd2\u7d20\u8f83\u591a\u7684\u60a3\u8005\u4e2d\uff0c\u4e3a\u4e86\u8fbe\u5230\u66f4\u9ad8\u7684Kt\/V\uff0c\u6cbb\u7597\u65f6\u95f4\u4ee5\u53ca\u4e0e\u900f\u6790\u5668\u6216\u7ba1\u8def\u7684\u63a5\u89e6\u65f6\u95f4\u66f4\u957f\uff0c\u8fd9\u53ef\u80fd\u662f\u7619\u75d2\u75c7\u4ea7\u751f\u7684\u539f\u56e0\u3002\u5bf9\u4e8eHD\u60a3\u8005Kt\/V\u8fbe\u6807\u540e\u4ecd\u6709\u4e25\u91cd\u7619\u75d2\u75c7\u7684\u60a3\u8005\uff0c\u53ef\u5c1d\u8bd5\u8fdb\u4e00\u6b65\u589e\u52a0\u900f\u6790\u5242\u91cf\u81f31.5\uff5e1.7\uff0c\u5bf9\u4e8eKt\/V&gt;1.7\u7684\u60a3\u8005\uff0c\u5e94\u5c06\u76ee\u6807Kt\/V\u964d\u81f3&lt;1.7\u3002\u4f7f\u7528\u751f\u7269\u4e0d\u76f8\u5bb9\u6027HD\u819c\u53ef\u80fd\u4f1a\u5bfc\u81f4\u90e8\u5206\u60a3\u8005\u51fa\u73b0\u7619\u75d2\u75c7\uff0c\u800c\u8fc7\u6e21\u5230\u4f7f\u7528\u751f\u7269\u76f8\u5bb9\u6027\u819c\uff08\u4f8b\u5982\u805a\u7532\u57fa\u4e19\u70ef\u9178\u7532\u916f\uff09\u900f\u6790\u53ef\u964d\u4f4e\u7619\u75d2\u75c7\u4e25\u91cd\u7a0b\u5ea6<sup>\uff3b58\uff3d<\/sup>\u3002\u4e0e\u4f4e\u901a\u91cf\u900f\u6790\u5668\u76f8\u6bd4\uff0c\u4f7f\u7528\u9ad8\u901a\u91cf\u900f\u6790\u5668\u53ef\u663e\u8457\u7f13\u89e3\u7619\u75d2\u75c7\u3002\u5bf9111\u4f8bCKD-aP\u60a3\u8005\u8fdb\u884c\u7684\u4e00\u9879\u4e3a\u671f5\u5e74\u7684\u524d\u77bb\u6027\u961f\u5217\u7814\u7a76\u8868\u660e\uff0c\u4e0e\u4f7f\u7528\u4f4e\u901a\u91cf\u900f\u6790\u5668\u76f8\u6bd4\uff0c\u65e0\u8bbaKt\/V\u662f\u5426\u22651.5\uff0c\u4f7f\u7528\u805a\u781c\u819c\u9ad8\u901a\u91cf\u900f\u6790\u5668\u60a3\u8005\u7684\u7619\u75d2\u75c7\u7a0b\u5ea6\u5747\u663e\u8457\u8f83\u4f4e<sup>\uff3b56\uff3d<\/sup>\u3002<\/p>\n<h3>\uff08\u56db\uff09&nbsp;\u80be\u79fb\u690d<\/h3>\n<p>\u80be\u79fb\u690d\u662fESKD\u60a3\u8005\u6cbb\u7597\u7684\u6700\u4f18\u7b56\u7565\uff0c\u4e5f\u662f\u7f13\u89e3CKD-aP\u60a3\u8005\u75c7\u72b6\u7684\u6709\u6548\u624b\u6bb5\u3002\u65e9\u57281986\u5e74\uff0cAltmeyer\u7b49<sup>\uff3b59\uff3d<\/sup>\u8bc1\u5b9e\u4e86\u8be5\u7ed3\u8bba\uff0c\u6240\u6709\u80be\u79fb\u690d\u540e\u7684\u60a3\u8005\u7619\u75d2\u75c7\u8fbe\u5230\u5b8c\u5168\u6d88\u5931\uff0c\u5c3d\u7ba1\u7ed3\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u4f46\u8be5\u7814\u7a76\u6837\u672c\u91cf\u5c0f\u4e14\u53ea\u8003\u8651\u4e86\u5168\u8eab\u7619\u75d2\uff0c\u5b58\u5728\u4e00\u5b9a\u5c40\u9650\u6027\u3002\u8fd1\u5e74\u6765\u591a\u9879\u7814\u7a76\u7ed3\u679c\u90fd\u8868\u660e\u80be\u79fb\u690d\u786e\u5b9e\u53ef\u4e0d\u540c\u7a0b\u5ea6\u5730\u6539\u5584CKD-aP\u3002Taylor\u7b49<sup>\uff3b18\uff3d<\/sup>\u5728521\u4f8b\u80be\u79fb\u690d\u53d7\u8005\u4e2d\u8fdb\u884c\u7684\u524d\u77bb\u6027\u7814\u7a76\u663e\u793a\uff0c\u5728\u63a5\u53d7\u80be\u79fb\u690d\u540e\u76843\u4e2a\u6708\uff0c23%\u60a3\u8005\u7619\u75d2\u75c7\u5f97\u5230\u6539\u5584\u3002Krajewski\u7b49<sup>\uff3b17\uff3d<\/sup>\u5bf9197\u4f8b\u80be\u79fb\u690d\u60a3\u8005\u5728\u79fb\u690d\u524d\u540e\u7684\u7619\u75d2\u75c7\u8fdb\u884c\u4e86\u5206\u6790\uff0c38.6%\uff0876\/197\uff09\u60a3\u8005\u5728\u900f\u6790\u671f\u95f4\u5b58\u5728\u7619\u75d2\u75c7\uff0c\u5176\u4e2d73.7%\uff0856\/76\uff09\u60a3\u8005\u5728\u63a5\u53d7\u80be\u79fb\u690d\u540e\u7619\u75d2\u75c7\u5f97\u5230\u5b8c\u5168\u7f13\u89e3\u3002\u7136\u800c\uff0c42\u4f8b\u80be\u79fb\u690d\u53d7\u8005\u4ecd\u5b58\u5728\u7619\u75d2\u75c7\uff0c\u5176\u4e2d52.4%\u662f\u5728\u80be\u79fb\u690d\u540e\u51fa\u73b0\u7684<sup>\uff3b17\uff3d<\/sup>\u3002\u4e00\u9879\u968f\u8bbf\u65f6\u95f4\u957f\u8fbe5\u5e74\u7684\u7eb5\u5411\u7814\u7a76\u663e\u793a\uff0c\u80be\u79fb\u690d\u540e\u60a3\u8005\u7619\u75d2\u75c7\u53ca\u808c\u8089\u75c9\u631b\u7684\u6539\u5584\u6700\u4e3a\u663e\u8457<sup>\uff3b60\uff3d<\/sup>\u3002<\/p>\n<h2>\u4e94\u3001&nbsp;\u603b\u7ed3<\/h2>\n<p>\u5c3d\u7ba1CKD-aP\u4e0eCKD\u60a3\u8005\u5c24\u5176\u662fHD\u60a3\u8005\u7684\u751f\u6d3b\u8d28\u91cf\u53ca\u8fdc\u671f\u75c5\u6b7b\u7387\u660e\u663e\u76f8\u5173\uff0c\u4f46CKD-aP\u4ecd\u7136\u88ab\u4f4e\u4f30\uff0c\u53d1\u75c5\u673a\u5236\u5c1a\u672a\u5b8c\u5168\u9610\u660e\uff0c\u4e14\u7279\u6548\u7684\u6cbb\u7597\u63aa\u65bd\u6709\u9650\u3002\u6b64\u5916\uff0c\u76ee\u524d\u5bf9CKD-aP\u6cbb\u7597\u7684\u7814\u7a76\u4e3b\u8981\u5173\u6ce8\u5728\u5355\u4e00\u6cbb\u7597\u63aa\u65bd\u5bf9\u7619\u75d2\u75c7\u7684\u6539\u5584\uff0c\u4f46CKD-aP\u4e0d\u4ec5\u662f\u5355\u7eaf\u7684\u7619\u75d2\uff0c\u8fd8\u4f1a\u5bfc\u81f4\u7761\u7720\u8d28\u91cf\u4e0b\u964d\u3001\u6291\u90c1\u3001\u611f\u67d3\u7b49\u4e00\u7cfb\u5217\u5e76\u53d1\u75c7\uff0c\u5bf9CKD-aP\u7684\u6709\u6548\u6cbb\u7597\u4e0d\u4ec5\u5e94\u6539\u5584\u7619\u75d2\u75c7\uff0c\u540c\u65f6\u9700\u8981\u5173\u6ce8\u5bf9\u5176\u4ed6\u5e76\u53d1\u75c7\u7684\u5f71\u54cd\u3002\u963f\u7247\u7c7b\u53d7\u4f53\u6fc0\u52a8\u5242\/\u62ee\u6297\u5242\u5728\u5927\u578b\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c\u4e2d\u663e\u793a\u51fa\u663e\u8457\u7597\u6548\uff0c\u6709\u671b\u6210\u4e3aHD\u60a3\u8005\u7619\u75d2\u75c7\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/p>\n<h2>\u5229\u76ca\u51b2\u7a81\u58f0\u660e<\/h2>\n<p>\u6240\u6709\u4f5c\u8005\u58f0\u660e\u65e0\u5229\u76ca\u51b2\u7a811.&nbsp;Kim D,&nbsp;Pollock C.&nbsp;Epidemiology and burden of chronic kidney disease-associated pruritus[J].&nbsp;Clin Kidney J,&nbsp;2021, 14 Suppl&nbsp;3&nbsp;:&nbsp;i1-i7.&nbsp;DOI:&nbsp;10.1093\/ckj\/sfab142.2.&nbsp;Gholyaf M,&nbsp;Sheikh V,&nbsp;Yasrebifar F,&nbsp;et al.&nbsp;Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study[J].&nbsp;Int Urol Nephrol,&nbsp;2020,&nbsp;52(6):&nbsp;1155-1165.&nbsp;DOI:&nbsp;10.1007\/s11255-020-02473-3.3.&nbsp;Shirazian S,&nbsp;Aina O,&nbsp;Park Y,&nbsp;et al.&nbsp;Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges[J].&nbsp;Int J Nephrol Renovasc Dis,&nbsp;2017,&nbsp;10:&nbsp;11-26.&nbsp;DOI:&nbsp;10.2147\/IJNRD.S108045.4.&nbsp;Rayner HC,&nbsp;Larkina M,&nbsp;Wang M,&nbsp;et al.&nbsp;International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis[J].&nbsp;Clin J Am Soc Nephrol,&nbsp;2017,&nbsp;12(12):&nbsp;2000-2007.&nbsp;DOI:&nbsp;10.2215\/CJN. 03280317.5.&nbsp;Hu X,&nbsp;Sang Y,&nbsp;Yang M,&nbsp;et al.&nbsp;Prevalence of chronic kidney disease-associated pruritus among adult dialysis patients: a meta-analysis of cross-sectional studies[J].&nbsp;Medicine (Baltimore),&nbsp;2018,&nbsp;97(21):&nbsp;e10633.&nbsp;DOI:&nbsp;10. 1097\/MD.0000000000010633.6.&nbsp;Sukul N,&nbsp;Karaboyas A,&nbsp;Csomor PA,&nbsp;et al.&nbsp;Self-reported pruritus and clinical, dialysis-related, and patient- reported outcomes in hemodialysis patients[J].&nbsp;Kidney Med,&nbsp;2021,&nbsp;3(1):&nbsp;42-53.e1.&nbsp;DOI:&nbsp;10.1016\/j.xkme.2020. 08.011.7.&nbsp;Pisoni RL,&nbsp;Wikstr\u00f6m B,&nbsp;Elder SJ,&nbsp;et al.&nbsp;Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].&nbsp;Nephrol Dial Transplant,&nbsp;2006,&nbsp;21(12):&nbsp;3495-3505.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfl461.8.&nbsp;Kimmel M,&nbsp;Alscher DM,&nbsp;Dunst R,&nbsp;et al.&nbsp;The role of micro- inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients[J].&nbsp;Nephrol Dial Transplant,&nbsp;2006,&nbsp;21(3):&nbsp;749-755.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfi204.9.&nbsp;Fallahzadeh MK,&nbsp;Roozbeh J,&nbsp;Geramizadeh B,&nbsp;et al.&nbsp;Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications[J].&nbsp;Nephrol Dial Transplant,&nbsp;2011,&nbsp;26(10):&nbsp;3338-3344.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfr053.10.&nbsp;Cevikbas F,&nbsp;Lerner EA.&nbsp;Physiology and pathophysiology of itch[J].&nbsp;Physiol Rev,&nbsp;2020,&nbsp;100(3):&nbsp;945-982.&nbsp;DOI:&nbsp;10.1152\/physrev.00017.2019.11.&nbsp;Kupczyk P,&nbsp;Reich A,&nbsp;Ho\u0142ysz M,&nbsp;et al.&nbsp;Opioid receptors in psoriatic skin: relationship with itch[J].&nbsp;Acta Derm Venereol,&nbsp;2017,&nbsp;97(5):&nbsp;564-570.&nbsp;DOI:&nbsp;10.2340\/00015555- 2595.12.&nbsp;Agarwal P,&nbsp;Garg V,&nbsp;Karagaiah P,&nbsp;et al.&nbsp;Chronic kidney disease-associated pruritus[J].&nbsp;Toxins (Basel),&nbsp;2021,&nbsp;13&nbsp;(8):&nbsp;527.&nbsp;DOI:&nbsp;10.3390\/toxins13080527.13.&nbsp;Fugal J,&nbsp;Serpa SM.&nbsp;Difelikefalin: a new \u03ba-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease-associated pruritus[J].&nbsp;Ann Pharmacother,&nbsp;2023,&nbsp;57(4):&nbsp;480-488.&nbsp;DOI:&nbsp;10.1177\/10600280221115889.14.&nbsp;Hu T,&nbsp;Wang B,&nbsp;Liao X,&nbsp;et al.&nbsp;Clinical features and risk factors of pruritus in patients with chronic renal failure[J].&nbsp;Exp Ther Med,&nbsp;2019,&nbsp;18(2):&nbsp;964-971.&nbsp;DOI:&nbsp;10.3892\/etm.2019.7588.15.&nbsp;Hsu CW,&nbsp;Weng CH,&nbsp;Chan MJ,&nbsp;et al.&nbsp;Association between serum aluminum level and uremic pruritus in hemodialysis patients[J].&nbsp;Sci Rep,&nbsp;2018,&nbsp;8(1):&nbsp;17251.&nbsp;DOI:&nbsp;10.1038\/s41598-018-35217-6.16.&nbsp;Jiang YM,&nbsp;Huang C,&nbsp;Peng Z,&nbsp;et al.&nbsp;Acidosis counteracts itch tachyphylaxis to consecutive pruritogen exposure dependent on acid-sensing ion channel 3[J].&nbsp;Mol Pain,&nbsp;2017,&nbsp;13:&nbsp;1744806917721114.&nbsp;DOI:&nbsp;10.1177\/1744806917721114.17.&nbsp;Krajewski PK,&nbsp;Olczyk P,&nbsp;Krajewska M,&nbsp;et al.&nbsp;Clinical characteristics of itch in renal transplant recipients[J].&nbsp;Front Med (Lausanne),&nbsp;2020,&nbsp;7:&nbsp;615334.&nbsp;DOI:&nbsp;10.3389\/fmed.2020.615334.18.&nbsp;Taylor K,&nbsp;Chu NM,&nbsp;Chen X,&nbsp;et al.&nbsp;Kidney disease symptoms before and after kidney transplantation[J].&nbsp;Clin J Am Soc Nephrol,&nbsp;2021,&nbsp;16(7):&nbsp;1083-1093.&nbsp;DOI:&nbsp;10.2215\/CJN. 19031220.19.&nbsp;Chor\u0105\u017cyczewska W,&nbsp;Reich A,&nbsp;Szepietowski JC.&nbsp;Lipid content and barrier function analysis in uraemic pruritus[J].&nbsp;Acta Derm Venereol,&nbsp;2016,&nbsp;96(3):&nbsp;402-403.&nbsp;DOI:&nbsp;10. 2340\/00015555-2266.20.&nbsp;Sukul N,&nbsp;Speyer E,&nbsp;Tu C,&nbsp;et al.&nbsp;Pruritus and patient reported outcomes in non-dialysis CKD[J].&nbsp;Clin J Am Soc Nephrol,&nbsp;2019,&nbsp;14(5):&nbsp;673-681.&nbsp;DOI:&nbsp;10.2215\/CJN. 09600818.21.&nbsp;Jovanovic DB,&nbsp;Pejanovic S,&nbsp;Vukovic L,&nbsp;et al.&nbsp;Ten years&#8217; experience in subtotal parathyroidectomy of hemodialysis patients[J].&nbsp;Ren Fail,&nbsp;2005,&nbsp;27(1):&nbsp;19-24.22.&nbsp;Papoiu AD,&nbsp;Emerson NM,&nbsp;Patel TS,&nbsp;et al.&nbsp;Voxel-based morphometry and arterial spin labeling fMRI reveal neuropathic and neuroplastic features of brain processing of itch in end-stage renal disease[J].&nbsp;J Neurophysiol,&nbsp;2014,&nbsp;112(7):&nbsp;1729-1738.&nbsp;DOI:&nbsp;10.1152\/jn.00827.2013.23.&nbsp;Abdallah AM,&nbsp;Elsheikh SM,&nbsp;ElBarbary RA.&nbsp;Prevalence and determinants of severity of uremic pruritus in hemodialysis patients: a multicentric study[J].&nbsp;J Investig Med,&nbsp;2023,&nbsp;71(1):&nbsp;42-46.&nbsp;DOI:&nbsp;10.1136\/jim-2022-002360.24.&nbsp;Chiu YL,&nbsp;Chen HY,&nbsp;Chuang YF,&nbsp;et al.&nbsp;Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients[J].&nbsp;Nephrol Dial Transplant,&nbsp;2008,&nbsp;23(11):&nbsp;3685-3689.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfn303.25.&nbsp;Ramakrishnan K,&nbsp;Bond TC,&nbsp;Claxton A,&nbsp;et al.&nbsp;Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms[J].&nbsp;Int J Nephrol Renovasc Dis,&nbsp;2013,&nbsp;7:&nbsp;1-12.&nbsp;DOI:&nbsp;10.2147\/IJNRD.S52985.26.&nbsp;Verduzco HA,&nbsp;Shirazian S.&nbsp;CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management[J].&nbsp;Kidney Int Rep,&nbsp;2020,&nbsp;5(9):&nbsp;1387-1402.&nbsp;DOI:&nbsp;10.1016\/j.ekir.2020.04.027.27.&nbsp;Gunal AI,&nbsp;Ozalp G,&nbsp;Yoldas TK,&nbsp;et al.&nbsp;Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial[J].&nbsp;Nephrol Dial Transplant,&nbsp;2004,&nbsp;19(12):&nbsp;3137-3139.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfh496.28.&nbsp;\u674e\u6797,&nbsp;\u6885\u957f\u6797,&nbsp;\u5b59\u4e3d\u541b,&nbsp;\u7b49.&nbsp;\u52a0\u5df4\u55b7\u4e01\u6cbb\u7597\u8840\u6db2\u900f\u6790\u60a3\u8005\u987d\u56fa\u6027\u5c3f\u6bd2\u75c7\u76ae\u80a4\u7619\u75d2\u7684\u4e34\u5e8a\u7814\u7a76[J].&nbsp;\u4e2d\u534e\u80be\u810f\u75c5\u6742\u5fd7,&nbsp;2010,&nbsp;26(5):&nbsp;335-338.&nbsp;DOI:&nbsp;10.3760\/cma.j.issn.1001- 7097.2010.05.003.29.&nbsp;Rayner H,&nbsp;Baharani J,&nbsp;Smith S,&nbsp;et al.&nbsp;Uraemic pruritus: relief of itching by gabapentin and pregabalin[J].&nbsp;Nephron Clin Pract,&nbsp;2012,&nbsp;122(3-4):&nbsp;75-79.&nbsp;DOI:&nbsp;10.1159\/000349943.30.&nbsp;Mathur VS,&nbsp;Kumar J,&nbsp;Crawford PW,&nbsp;et al.&nbsp;A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus[J].&nbsp;Am J Nephrol,&nbsp;2017,&nbsp;46(6):&nbsp;450-458.&nbsp;DOI:&nbsp;10.1159\/000484573.31.&nbsp;Peer G,&nbsp;Kivity S,&nbsp;Agami O,&nbsp;et al.&nbsp;Randomised crossover trial of naltrexone in uraemic pruritus[J].&nbsp;Lancet,&nbsp;1996,&nbsp;348(9041):&nbsp;1552-1554.&nbsp;DOI:&nbsp;10.1016\/s0140-6736(96)04176-1.32.&nbsp;Legroux-Crespel E,&nbsp;Cl\u00e8des J,&nbsp;Misery L.&nbsp;A comparative study on the effects of naltrexone and loratadine on uremic pruritus[J].&nbsp;Dermatology,&nbsp;2004,&nbsp;208(4):&nbsp;326-330.&nbsp;DOI:&nbsp;10.1159\/000077841.33.&nbsp;Wieczorek A,&nbsp;Krajewski P,&nbsp;Kozio\u0142-Ga\u0142czy\u0144ska M,&nbsp;et al.&nbsp;Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus[J].&nbsp;J Eur Acad Dermatol Venereol,&nbsp;2020,&nbsp;34(10):&nbsp;2368-2372.&nbsp;DOI:&nbsp;10. 1111\/jdv.16360.34.&nbsp;Phan NQ,&nbsp;Bernhard JD,&nbsp;Luger TA,&nbsp;et al.&nbsp;Antipruritic treatment with systemic \u03bc-opioid receptor antagonists: a review[J].&nbsp;J Am Acad Dermatol,&nbsp;2010,&nbsp;63(4):&nbsp;680-688.&nbsp;DOI:&nbsp;10.1016\/j.jaad.2009.08.052.35.&nbsp;Wikstr\u00f6m B,&nbsp;Gellert R,&nbsp;Ladefoged SD,&nbsp;et al.&nbsp;Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies[J].&nbsp;J Am Soc Nephrol,&nbsp;2005,&nbsp;16(12):&nbsp;3742-3747.&nbsp;DOI:&nbsp;10.1681\/ASN.2005020152.36.&nbsp;Kumagai H,&nbsp;Ebata T,&nbsp;Takamori K,&nbsp;et al.&nbsp;Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase\u2162, randomized, double-blind, placebo-controlled study[J].&nbsp;Nephrol Dial Transplant,&nbsp;2010,&nbsp;25(4):&nbsp;1251-1257.&nbsp;DOI:&nbsp;10.1093\/ndt\/gfp588.37.&nbsp;Kumagai H,&nbsp;Ebata T,&nbsp;Takamori K,&nbsp;et al.&nbsp;Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients[J].&nbsp;Am J Nephrol,&nbsp;2012,&nbsp;36(2):&nbsp;175-183.&nbsp;DOI:&nbsp;10.1159\/000341268.38.&nbsp;Zhang P,&nbsp;Xiang S,&nbsp;Liu B,&nbsp;et al.&nbsp;Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients[J].&nbsp;Ren Fail,&nbsp;2023,&nbsp;45(1):&nbsp;2175590.&nbsp;DOI:&nbsp;10.1080\/0886022X.2023.2175590.39.&nbsp;Inui S,&nbsp;Shirakawa Y,&nbsp;Itami S.&nbsp;Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients[J].&nbsp;J Dermatol,&nbsp;2012,&nbsp;39(10):&nbsp;886-&nbsp;887.&nbsp;DOI:&nbsp;10.1111\/j.1346-8138.2011.01442.x.40.&nbsp;Weisshaar E,&nbsp;Dunker N,&nbsp;R\u00f6hl FW,&nbsp;et al.&nbsp;Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients[J].&nbsp;Exp Dermatol,&nbsp;2004,&nbsp;13(5):&nbsp;298-304.&nbsp;DOI:&nbsp;10.1111\/j.0906-6705.2004. 00184.x.41.&nbsp;Feily A,&nbsp;Dormanesh B,&nbsp;Ghorbani AR,&nbsp;et al.&nbsp;Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients[J].&nbsp;Int J Clin Pharmacol Ther,&nbsp;2012,&nbsp;50(7):&nbsp;510-513.&nbsp;DOI:&nbsp;10.5414\/cp201629.42.&nbsp;Simonsen E,&nbsp;Komenda P,&nbsp;Lerner B,&nbsp;et al.&nbsp;Treatment of uremic pruritus: a systematic review[J].&nbsp;Am J Kidney Dis,&nbsp;2017,&nbsp;70(5):&nbsp;638-655.&nbsp;DOI:&nbsp;10.1053\/j.ajkd.2017.05.018.43.&nbsp;Cupisti A,&nbsp;Piccoli GB,&nbsp;Gallieni M.&nbsp;Charcoal for the management of pruritus and uremic toxins in patients with chronic kidney disease[J].&nbsp;Curr Opin Nephrol Hypertens,&nbsp;2020,&nbsp;29(1):&nbsp;71-79.&nbsp;DOI:&nbsp;10.1097\/MNH. 0000000000000567.44.&nbsp;Pakfetrat M,&nbsp;Malekmakan L,&nbsp;Hashemi N,&nbsp;et al.&nbsp;Sertraline can reduce uremic pruritus in hemodialysis patient: a double blind randomized clinical trial from Southern Iran[J].&nbsp;Hemodial Int,&nbsp;2018,&nbsp;22(1):&nbsp;103-109.&nbsp;DOI:&nbsp;10.1111\/hdi.12540.45.&nbsp;Mahmudpour M,&nbsp;Roozbeh J,&nbsp;Raiss Jalali GA,&nbsp;et al.&nbsp;Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients[J].&nbsp;Iran J Kidney Dis,&nbsp;2017,&nbsp;11(1):&nbsp;50-55.46.&nbsp;Young TA,&nbsp;Patel TS,&nbsp;Camacho F,&nbsp;et al.&nbsp;A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients[J].&nbsp;J Dermatolog Treat,&nbsp;2009,&nbsp;20(2):&nbsp;76-81.&nbsp;DOI:&nbsp;10.1080\/09546630802441218.47.&nbsp;Tarng DC,&nbsp;Cho YL,&nbsp;Liu HN,&nbsp;et al.&nbsp;Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream[J].&nbsp;Nephron,&nbsp;1996,&nbsp;72&nbsp;(4):&nbsp;617-622.&nbsp;DOI:&nbsp;10.1159\/000188949.48.&nbsp;Griffin N,&nbsp;Zimmerman DD,&nbsp;Briel JW,&nbsp;et al.&nbsp;Topical L-arginine gel lowers resting anal pressure: possible treatment for anal fissure[J].&nbsp;Dis Colon Rectum,&nbsp;2002,&nbsp;45(10):&nbsp;1332-1336.&nbsp;DOI:&nbsp;10.1007\/s10350-004-6420-9.49.&nbsp;Tseng CY,&nbsp;Wu TT,&nbsp;Lai CW,&nbsp;et al.&nbsp;Vegetarian diet may ameliorate uremic pruritus in hemodialysis patients[J].&nbsp;Ren Fail,&nbsp;2018,&nbsp;40(1):&nbsp;514-519.&nbsp;DOI:&nbsp;10.1080\/0886022X.2018.1512871.50.&nbsp;Heydarbaki M,&nbsp;Amerian M,&nbsp;Abbasi A,&nbsp;et al.&nbsp;The effects of omega-3 on the sleep quality of patients with uremic pruritus undergoing hemodialysis: a randomized crossover study[J].&nbsp;J Complement Integr Med,&nbsp;2020,&nbsp;18(1):&nbsp;217-222.&nbsp;DOI:&nbsp;10.1515\/jcim-2019-0081.51.&nbsp;Thatiparthi A,&nbsp;Martin A,&nbsp;Liu J,&nbsp;et al.&nbsp;Risk of skin cancer with phototherapy in moderate-to-severe psoriasis: an updated systematic review[J].&nbsp;J Clin Aesthet Dermatol,&nbsp;2022,&nbsp;15(6):&nbsp;68-75.52.&nbsp;Sapam R,&nbsp;Waikhom R.&nbsp;Role of narrow band ultra violet radiation as an add-on therapy in peritoneal dialysis patients with refractory uremic pruritus[J].&nbsp;World J Nephrol,&nbsp;2018,&nbsp;7(4):&nbsp;84-89.&nbsp;DOI:&nbsp;10.5527\/wjn.v7.i4.84.53.&nbsp;K\u0131l\u0131\u00e7 Ak\u00e7a N,&nbsp;Ta\u015fc\u0131 S.&nbsp;Acupressure and transcutaneous electrical acupoint stimulation for improving uremic pruritus: a randomized, controlled trial[J].&nbsp;Altern Ther Health Med,&nbsp;2016,&nbsp;22(3):&nbsp;18-24.54.&nbsp;Yan CN,&nbsp;Yao WG,&nbsp;Bao YJ,&nbsp;et al.&nbsp;Effect of auricular acupressure on uremic pruritus in patients receiving hemodialysis treatment: a randomized controlled trial[J].&nbsp;Evid Based Complement Alternat Med,&nbsp;2015,&nbsp;2015:&nbsp;593196.&nbsp;DOI:&nbsp;10.1155\/2015\/593196.55.&nbsp;Hiroshige K,&nbsp;Kabashima N,&nbsp;Takasugi M,&nbsp;et al.&nbsp;Optimal dialysis improves uremic pruritus[J].&nbsp;Am J Kidney Dis,&nbsp;1995,&nbsp;25(3):&nbsp;413-419.&nbsp;DOI:&nbsp;10.1016\/0272-6386(95)90102-7.56.&nbsp;Ko MJ,&nbsp;Wu HY,&nbsp;Chen HY,&nbsp;et al.&nbsp;Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study[J].&nbsp;PLoS One,&nbsp;2013,&nbsp;8(8):&nbsp;e71404.&nbsp;DOI:&nbsp;10.1371\/journal.pone.0071404.57.&nbsp;Duque MI,&nbsp;Thevarajah S,&nbsp;Chan YH,&nbsp;et al.&nbsp;Uremic pruritus is associated with higher kt\/V and serum calcium concentration[J].&nbsp;Clin Nephrol,&nbsp;2006,&nbsp;66(3):&nbsp;184-191.&nbsp;DOI:&nbsp;10.5414\/cnp66184.58.&nbsp;Lin HH,&nbsp;Liu YL,&nbsp;Liu JH,&nbsp;et al.&nbsp;Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney[J].&nbsp;Artif Organs,&nbsp;2008,&nbsp;32(6):&nbsp;468-472.&nbsp;DOI:&nbsp;10.1111\/j.1525-1594. 2008.00568.x.59.&nbsp;Altmeyer P,&nbsp;Kachel HG,&nbsp;Sch\u00e4fer G,&nbsp;et al.&nbsp;[Normalization of uremic skin changes following kidney transplantation][J].&nbsp;Hautarzt,&nbsp;1986,&nbsp;37(4):&nbsp;217-221.60.&nbsp;Amro A,&nbsp;Waldum-Grevbo B,&nbsp;von der Lippe N,&nbsp;et al.&nbsp;Symptom clusters from dialysis to renal transplantation: a five-year longitudinal study[J].&nbsp;J Pain Symptom Manage,&nbsp;2016,&nbsp;51(3):&nbsp;512-519.&nbsp;DOI:&nbsp;10.1016\/j.jpainsymman.2015. 10.012.<\/p>\n<p>\u5f15\u7528\u672c\u6587\uff1a&nbsp;\u6c64\u6653\u9759, \u6885\u957f\u6797. \u8840\u6db2\u900f\u6790\u60a3\u8005\u7619\u75d2\u75c7\u7684\u53d1\u75c5\u673a\u5236\u53ca\u836f\u7269\u6cbb\u7597\u8fdb\u5c55[J]. \u4e2d\u534e\u80be\u810f\u75c5\u6742\u5fd7, 2024, 40(1): 61-66. DOI: 10.3760\/cma.j.cn441217-20230413-00420.<\/p>\n<p>\u6587\u7ae0\u7f16\u53f7\uff1a1001-7097\uff082024\uff0901-0061-06<\/p>\n<p>\u6536\u7a3f\u65e5\u671f\uff1a2023-04-13<\/p>\n<p>\u51fa\u7248\u65e5\u671f\uff1a2024-01-15<\/p>\n<p>\u7f51\u520a\u53d1\u5e03\u65e5\u671f\uff1a2024-01-20<\/p>\n<p>\u672c\u6587\u7f16\u8f91\uff1a\u5f6d\u82d7&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6c64\u6653\u9759&nbsp;&nbsp;\u6885\u957f\u6797 \uff08\u6d77\u519b\u519b\u533b\u5927\u5b66\u7b2c\u4e8c\u9644\u5c5e\u533b\u9662\u80be\u810f\u75c5\u79d1\uff0c\u4e0a\u6d77  &hellip; <a href=\"http:\/\/zydq.1006ss.com\/?p=38130\">\u7ee7\u7eed\u9605\u8bfb <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"class_list":["post-38130","post","type-post","status-publish","format-standard","hentry","category-70"],"_links":{"self":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/38130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38130"}],"version-history":[{"count":0,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/38130\/revisions"}],"wp:attachment":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38130"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}